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ABSTRACT 
Pyrithione (2-mercaptopyridine-N-oxide; Omadine) showed broad-spectrum 
antimicrobial activity with Gram-positive bacteria and yeasts being more sensitive than 
Gram-negative bacteria. This study examines the growth and survival profIles of 
Klebsiella pneumoniae in the presence of pyrithione . Studies of growth and survival of 
Bacillus licheniformis and Candida albicans are included for comparative purposes. 
In the presence of the drug , Kt. pneumoniae and B. licheniformis exhibited 
similar growth patterns, namely a drug concentration-dependent Jag phase followed by 
growth at a rate similar to that of untreated cells. In contrast, C. albicans exhibited a 
drug concentration-dependent rate of growth . Viable counts of Kl. pneumoniae and 
C. albicans in the presence of pyrithione , mirrored the growth patterns observed by 
turbidity measurements . 
Size analysis of ampicillin-treated ( divisioniess ) cells of Kl. pneumoniae in the 
presence and absence of pyrithione , suggested that all cells are inhibited from growth 
during the lag phase, and re-growth is due to recovery of all cells rather than the growth 
of a resistant population within the culture . 
Bacteria grown in the presence of sub-inhibitory concentrations of pyrithione were 
insensitive to further challenge with the same concentrations of the drug . The resistance 
of Kl. pneumoniae was maintained during 7 days of subculture in drug-free medium , 
but fell to a lower level after 4 days of subculture , and cross-resistance to 
chloramphenicol was observed, but not to 8-hydroxyquinoline . The fatty acid profIle 
of pyrithione-sensitive and pyrithione-resistant Kt. pneumoniae are essentially similar . 
Cells of B. licheniformis grown in the presence of pyrithione showed no cross-
resistance with any of the antimicrobial agents tested . 
Pyrithione also inhibited the incorporation of 14C-glycine , 14C-thyrnidine and 
14C-urldine in both Kl. pneumoniae and B. licheniformis . Further investigation 
showed that in Kl. pneumoniae ,only the 14C-uridine uptake profIle resembled the 
iii 
growth inhibition profIle. Pyrithione , at sub-inhibitory concentration, caused 70% 
inhibition of the activity of purified Escherichia coli RNA polymerase in vitro. 
Scanning electron microscopy showed that some cells of Kt. pnewnoniae underwent 
elongation upon prolonged incubation ( 24 hours) in the presence of pyrithione 
approaching the minimum inhibitory concentration. The morphology of 
B. licheniformis was not significantly affected by pyrithione , but the drug caused some 
damage to the cell surface in C. albicans when at concentrations approaching the 
minimum inhibitory concentration. 
It is concluded that pyrithione has more than one mode of action. Results are 
discussed in the light of pyrithione having an indirect effect on protein synthesis in 
Kt. pneumoniae , perhaps by interfering with RNA synthesis at the RNA polymerase 
level. 
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ABBREVIATIONS 
ATP Adenosine-S'-triphosphate 
COM Chemically defined medium 
COMA Chemically defined medium agar 
CfP Cytidine-S-triphosphate 
DNA Deoxyribonucleic acid 
EDTA Ethylendiaminetetraacetic acid 
FAME Fatty acids methyl esters 
GLC Gas Liquid chromatography 
GTP Guanosine-S'-triphosphate 
MIC Minimum inhibitory concentration 
NA Nutrient agar 
RNA Ribonucleic acid 
tRNA transfer Ribonucleic acid 
TTP Thymidine-S' -triphosphate 
UTP Uridine-S'-triphosphate 
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CHAPTER ONE 
INTRODUCTION 
1.1. Targets for Antimicrobial Agents in the Bacterial Cell 
1.1.1. The Cell WaIl 
The bacterial cell wall is a complex sttucture composed of a range of molecules, 
many of which are not found elsewhere in nature . The cell wall polymers function as 
an envelope to protect the protoplast surrounded by its delicate cytoplasmic membrane, 
and to confer the characteristic shape on the bacterium. They also contain on their 
outside surface sites for (1) the adsorption of bacteriophages , (2) the recognition and 
transport of certain substances and (3) cell-cell recognition and interaction (Gale et ai, 
1981) . Bacteria are divided into two main groups according to their reaction to Gram-
stain . This division reflects the difference in the chemical composition of the cell wall 
between Gram-positive and Gram-negative bacteria (Table 1.1) . 
Table 1.1 Bacterial Cell Wall Polymers (Gale et at , 1981 ) 
Polymer Gram-positive Gram-negative 
Peptidoglycan + + 
Teichoic and / or teichuronic acid + 
Lipopolysaccharides + 
Lipoprotein + 
PhosphopJipid + 
Protein +/- + 
Polysaccharide +/-
1 
Peptidoglycan is a polymer found in cell walls of both Gram-positive and Gram-
negative bacteria. It consists of a macromolecular net work made up from linear glycan 
strands of B-(1,4)- linked N-acetylglucosamine and N-acetylmuramic acid 
(Fig. !.la) . The glycan strands are cross-linked by peptide substituents : oligopeptide 
chains containing a sequence of L- and D- amino acids are present on each 
N-acetylmuramic acid residue. Some of these peptides are cross-linked, and the 
nature of the cross-link is a feature distinguishing peptidoglycans from different 
organisms (Lambert, 1988) . In addition to the peptidoglycan layer, the simpler 
Gram-positive wall contains teichoic acid. The Gram-negative cell wall is more 
complex and contains outer layers of lipopolysaccharide and lipoprotein ( comprising 
the outer-membrane) in addition to peptidoglycan (Fig. 1. 1 b) . The structure of the 
bacterial cell wall has been extensively reviewed ( Salton , 1962, 1964; Schleifer and 
Kandler, 1972; Costenon and Cheng, 1975; Schleifer and Stackebrandt, 1983; 
Lamben, 1983 , 1988 ; Schleifer , 1985 ) . 
The biosynthesis of the peptidoglycan layer is the target for many antibiotics and 
antimicrobial agents, notably B-lactam antibiotics. B-lactam antibiotics have the ability 
to bind and inbibit a group of proteins, hence known as penicillin binding proteins 
(PBP) , associated with various enzymic activities and functions in peptidoglycan 
synthesis ( Spran and Pardee , 1975 ; Spran, 1977) . Other antibiotics and 
antimicrobial agents acting on peptidoglycan synthesis include cycloserine, 
vancomycin and bacitracin. Figure 1.2 shows the various stages of peptidoglycan 
synthesis and the effects of antibiotics. The mode of action of bacterial cell wall 
synthesis inhibitors have been reviewed (Salton and Tomasz , 1974 ; Gale et al , 
1981 ; Franklin and Snow, 1989) . 
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Figure 1.1 (a) Cross-linked peptidoglycan arrangement in Staphylococcus aureus . 
NAM , N-acetylmuramic acid; NAG, N-acetylglucosarnine ; L-ala , L-alanine : 
L-lys , L-lysine ; gly , glycine; D-ala, D-alanine ; D-glu , D-glutamate . 
( Edwards , 1980 ) 
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(b) Diagrammatic representation of the (a) Gram-negative and (b) Grain-
positive .cell envelopes: CW , cell wall; PS periplasm ; CM , cytoplasmic 
membrane; CMP , cytoplasmic membrane protein; OM , outer membrane; G , 
glycocalyx ; OMP , outer-membrane protein; LPS , lipopolysaccharide; PL , 
phospholipid; LP ,lipoprotein; PP , porin protein; TA, teichoic acid; PG , 
peptidoglycan. ( Gilben ,1988 ) . 
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Figure 1.2. Peptidoglycan synthesis in Escherichia coli, and the effect of 
antibiotics. NAG, N-acetylglucosarnine ; PEP, Phosphoenolpyruvate; 
NAM , N-acetylmurarnic acid. (Quesnel and Russell , 1983) . 
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1.1.2. The Cell Membrane 
The cytoplasmic membrane is a thin structure that completely surrrounds the 
bacterial cell. It consists of a phospholipid bilayer liberally studded with a wide variety 
of polypeptides (Hancock and Nicas , 1984 ) . The currently accepted model of the 
membrane is that suggested by Singer and Nicholson (1972) , namely, the fluid 
mosaic model shown in Figure 1.3 . 
The cytoplasmic membrane is a dynamic structure containing at least 40% fluid 
lipids and is a critical permeability barrier vital to the function of the cell (Kabara , 
1984) . The major functions of the cytoplasmic membrane proteins include energy 
generation (e.g. ,electron-transport chain carrier proteins and Ca2+. Mg2+_ stimulated 
ATPase) ; active and facilitated transpon of nutrients and expon of toxic products, and 
enzymic synthesis of cell wall components (Hancock and Nicas , 1984). The structure 
and composition of the cytoplasmic membrane have been reviewed ( Hughes , 1962 ; 
Salton and Owen, 1976; Edwards, 1980; Gale et a[, 1981 ; Hugo, 1983). 
Many antimicrobial agents affect the cytoplasmic membrane function and they can 
be divided into the following groups (Gale et a[ , 1981) : 
(l) drugs causing major disorganisation of the cytoplasmic membrane such, e.g. 
tyrocidins, phenols and polymyxins ; 
(2) drugs that produce aqueous pores in membranes thus disturbing the controlled 
transport of substances across the membrane, e.g. gramicidines and polyene antibiotics 
(mainly antifungal) ; 
(3) drugs causing specific changes in cation permeability (ionophores) , e.g. 
dinitrophenyl and valinomycin ; 
(4) drugs that inhibit membrane-bound enzymes involved in energy transfer. e.g. 
Chlorhexidine and dicyclocarbodiimide ; 
(5) inhibitors of enzymes involved in the synthesis of essential components of 
membrane. such as ceruJenin which inhibits fatty acid synthesis. 
5 
The mode of action of antimicrobial agents against the cytoplasmic membrane has 
been reviewed (Salton and Tomasz, 1974; Gale et ai, 1981 ; Franklin and Snow, 
1989) . 
Figure 1.3 Fluid mosaic membrane model. The solid bodies represent globular 
proteins which are immersed in the lipid bilayer ( Singer and Nicholson, 
1972) . 
6 
1.1.3. Nucleic Acids 
The chromosome of the bacterial cell consists of a single circular molecule of 
double stranded DNA. In general, drugs which inhibit nucleic acid function are not 
especially selectively toxic since the mechanisms of nucleotide synthesis, replication 
and transcription are very similar in both prokaryotic and eukaryotic cells (Edwards , 
1980) . 
Gale et a1 (1981) defmed three levels at which inhibitors of nucleic acid synthesis 
may exen their primary effect. The first group include those agents which interfere 
with nucleotide metabolism. Examples of this group include azaserine which inhibits 
pwine synthesis, 5-fluorouracil which inhibits nucleotide interconversion , cytosine 
arabinoside inhibiting nucleotide utilisation and 5-iododeoxyuridine which serves as an 
unnatural substtate that is incorporated into polynucleotides causing distonion to the 
structure and function of the nucleic acid. 
The second group includes agents that impair the template function of the DNA. 
Classical examples of this group of compounds are the intercalating drugs ethidium 
and proflavine. Because of their planar ring structure and their width corresponding 
with that of a base pair (0.34 nm) , these drug molecules are insened into the DNA 
helix causing frameshift mutagenesis, and subsequent inhibi~ of the function of 
DNA. 
Compounds that inhibit enzymic processes in nucleic acid synthesis comprise the 
third and final group in this division. Rifampicin, for example, selectively binds and 
inhibits RNA polymerase in bactria , whilst nalidixic acid and its analogues interfere 
with DNA synthesis by inhibiting the enzyme DNA gyrase (pedrini , 1979; 
Cozzarelli , 1977 , 1980) . The mode of action of nucleic acid biosynthesis inhibitors 
has been reviewed by Gale et al (1981) and Franklin and Snow (1989) . 
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) 1.4. Ribosomes 
Ribosomes are the centres of protein synthesis .In bacteria they are composed of 
RNA and protein in the mass ratio 65 : 35 , respectively, and contain 80-90% of the 
total cellular RNA (Gale et al ,1981) . Ribosomes of prokaryotic cells can be 
distinguished from those of eukaryotic cells on the basis of their sedimentation 
coefficients ('S' values) . Ribosomes of bacteria and blue-green algae have a 
sedimentation coefficient of 70S, and each ribosome dissociates to give 30S and 50S 
particles. In fungi, yeasts , algae and protozoa, 80S ribosomes are synthesized and 
each is built of one 60S and one 40S particle (Rose, 1968). Aggregation of ribosomal 
particles is brought about and regulated by varying concentration of Mg2+ ( Rose , 
1968) . 
Inhibitors of ribosomal function in bacteria are classified on the basis of their site of 
action, that is , whether they bind primarily to the 30S or 50S ribosomal subunit (Table 
1.2) . Inhibitors of the smaller 30S unit include tetracyclines which inhibits the binding 
of aminoacyl-tRNA to the acceptor site on the ribosome, and aminoglycosides such as 
streptomycin, Neomycin and Gentamycin also bind to the 30S subunit causing 
misreading of the genetic code (Davis , 1988) . Drugs acting at the 50S subunit include 
chloramphenicol which inhibits peptide bond formation ( and therefore peptide 
elongation) through inhibition of the peptidyltransferase reaction, and macrolides such 
as erythromycin which act by stimulating the dissociation of peptidyl-tRNA from 
ribosomes thus interrupting the completion of peptide chains (Franklin and Snow, 
1989) . 
The mode of action of ribosomal function inhibitors has been reviewed (Gale et al , 
1981 ; Franklin and Snow, 1989) . 
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Table 1.2 Classification of protein synthesis inhibitors ( Edwards , 1980 ) 
Drugs acting on the 30S ribosomal subunit 
The aminoglycoside antibiotics 
The tetracyclines 
Drugs acting on the 50S ribosomal subunit 
Puromycin 
chloramphenicol 
Erythromycin 
Lincomycin 
Clindarnycin 
Fusidic acid 
1.1.S,Metabolism 
Some antibacterial agents act by specifically inhibiting some enzymic reactions, 
Both sulphonamides and trimethoprirn belong to this group of compounds and act by 
inhibiting the biosynthesis of folic acid which is essential to the production of nucleic 
acid constituents, Sulphonamides interfere with folic acid biosynthesis at the earlier 
stage by competing with p-aminobenzoic acid (PABA) for the active site on the 
enzyme dihydropteroic acid synthetase, Trimethoprim acts at a later stage by binding 
and inhibiting the enzyme dihydrofolate reductase (Franklin and Snow, 1989 ), 
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1.2. Bacterial Resistance to Antimicrobial Agents 
1.2.1. Introduction 
Micro-OI'ganisms are capable of establishing resistance towards substances which 
normally have a selective lethal 01' inhibitory action against them. Thus resistance can 
be defined as the temporary 01' pemtanent ability of an OI'ganism and its progeny to 
remain viable and multiply under environmental conditions that would destroy or inhibit 
other cells (Lambert and Hammond , 1983) . Bacterial resistance to antimicrobial agents 
has always attracted intense interest since it poses an obviously serious problem in the 
treatment of infectious diseases (Moyed , 1964) , preservation of phannaceutical 
products (Gilben , 1988) and disinfection (Lamben and Harnmond , 1983) . 
A distinction can be made between 'inherent' and 'acquired' resistance of bacteria to 
antibacterial agents (Franklin, 1983) . Cenain bacteria, such as Gram-negative 
bacteria, are generally more resistant to antimicrobial agents. This 'inherent' resistance 
of Gram-negative bacteria has been attributed to the impermeability of the complex 
outer membrane to some drugs which, with periplasmic enzymes, may prevent the 
attainment of an inhibitory concentration within the cell ( Franklin , 1983 ; Nikaido , 
1988 ) . Furthermore, within the Gram-negative group, Pseudomonas aeruginosa 
and Klebsiella pneumoniae are inherently more resistant to many antimicrobial agents 
( Brown, 1975) . 
The acquired ability of bacteria to grow and multiply in the presence of an 
antimicrobial agent may reflect a difference in the genetic makeup between these and 
sensitive OI'ganisms (Franklin , 1983) . When a bacterial population adapts to the 
presence of an antimicrobial agent, sensitive cells are gradually replaced by resistant 
cells. Such resistance may be acquired through spontaneous mutations at appropriate 
genetic loci, and the resulting resistant mutants will eventually overgrow and replace 
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sensitive cells in the presence of an antimicrobial agent. Alternatively, genetic material 
conferring resistance may be transferred from one cell to another through processes 
such as conjugation, transduction or transformation (Franldin , 1983) . These 
mechanisms of acquisition of resistance will not be discussed here, but the biochemical 
mechanisms of bacterial resistance to antimicrobial agents will be examined more 
closely using representative examples. 
1.2.2. Biochemical mechanisms of resistance 
A number of mechanisms have been demonstrated : 
(1) Conversion of active drug to an inactive derivative by enzyme(s) produced by 
resistant cells. 
The most important mechanism of bacterial resistance to B-lactam antibiotics is 
through hydrolysis of the B-lactam ring by B-lactamases (Bryan , 1988) . B-La.ctamases 
are generally induced in both Gram-negative (Jacoby and Sunon,1985) and Gram-
positive bacteria (Lyon and Skurray , 1987; Boyce et ai, 1990 ) by the presence of 
minute quantities of B-lactam antibiotics. However, B-lactamases of Gram-positive 
bacteria act in a different manner from those of Gram-negative organisms (Bryan , 
1988) . Generally, Gram-positive B-lactamases are released into the medium, whereas 
those from Gram-negative bacteria, typically remain within the periplasmic space 
through wbich the B-lactam must pass during cellular uptake (Bryan, 1988; Franklin 
and Snow, 1989) . 
Another important example of bacterial resistance due to antibiotic inactivation is the . 
enzyrnatic acetylation of chloramphenicol ( Sands and Shaw , 1973 ; Roberts et al , 
1985 ; Martinez-Suarez et ai, 1985; Powell et ai, 1989) . The enzyme responsible, 
chloramphenicol acetyltransferase (CAT) converts chloramphenicol 10 the 
microbiologically inactive 3-acetoxy derivative using acetyl-CoA as an essential 
cofactor (Franklin and Snow, 1989) . 
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(2) Modification of the drug-sensitive site. 
A common example of the modification of a drug-sensitive site resulting in a high 
level of resistance is the loss of ribosomal sensitivity to streptomycin ( Eliopoulos et 
al. 1984 ) . The change in ribosomal structure has been traced to a single amino acid 
replacement in either of two positions in the S 12 protein of the 30S ribosomal subunit . 
The modified 30S subunit no longer binds streptomycin and the drug no longer inhibits 
protein synthesis ( Franklin and Snow. 1989 ) . 
Similarly. the resistance of Mycobacterium tuberculosis ro other protein synthesis 
inhibitors. such as viomycin and kanamycin. is believed to result from shifts in 
ribosomal structure ( Yamada et al • 1985 ) . Escherichia coli resistance to quinolone 
antibiotics. such as nalidixic acid. may also be due to an altered DNA gyrase • the 
usual target enzyme (Piddock and Wise. 1989). 
(3) Loss of cell permeability to a drug . 
The bacterial cell envelope is a natural barrier to the penneation of antimicrobial 
agents into Gram-negative and Gram-positive cells ( Costenon and Cheng • 1975 ) . 
The outer-membrane present in Gram-negative bacteria is itself an additional barrier that 
in pan explains the resistance of Gram-negative bacteria to many antimicrobial agents 
( Nikaido • 1988 ) . However. more specific mechanisms of resistance associated with 
reduced penneability to certain drugs do exist. For example. bacterial resistance to 
tetracyclines is the result of an efflux energy-dependent process that specifically pumps 
tetracyclines out of the cell against a concentration gradient (Durckheimer. 1975 ; 
Chopra and Howe • 1978 ; McMurty et al • 1987 ; Park et al • 1987 ) . 
Chloramphenicol resistance in Gram-negative bacteria such as Haemophilus 
injluenzae and Pseudomonas species has been shown to be mediated by the absence 
of a porin protein from the outer membranes of these organisms. resulting in reduced 
uptake of the drug (Burns et al. 1985. 1986. 1989) . Similar alterations in the outer 
membrane proteins are also responsible for the reduced uptake of some 8-1actarn 
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antibiotics such as impenem by Enterobacter aerogenes (Hopkins and Towner , 1990 ) 
and Pseudomonas aeruginosa (Bellido et aJ , 1990) . 
(4) Synthesis of an additional drug-resistant ( target) enzyme. 
Bacterial resistance to sulphonamides and trimethoprim examplifies the synthesis of 
additional drug-resistant fonns of the target enzyme. In the case of sulphonamides, 
drug-resistant variants of the target enzyme ( dihydropteroate synthetase) are produced 
which have lower affmities to the drugs (Swedberg, 1987 ; Facirelli and Varaldo, 
1987 ) . Similarly, the production of drug-resistant variants of the enzyme 
dihydrofolate reductase confers resistance in bacteria to trimethoprim (Huovinen , 
1987; Wylie and Koornhof, 1989; Heikkila et aJ; 1990). Such mechanism of 
resistance is also seen as a case where the organism utilises an alternative metabolic 
pathway that is less sensitive to the antimicrobial agent (Franklin and Snow, 1989 ). 
(5) Increased production of a metabolite that antagonises the inhibitor. 
When a drug inhibits microbial growth by the competitive antagonism of a normal 
metabolite , resistance may be due to increased production of the metabolite . The 
hyperproduction of p-aminobenzoic acid ( the natural substrate for the enzyme 
dihydropteroate synthetase) with which sulphonamides are believed to compete for the 
active site on the enzyme, is an example of this mechanism of resistance ( Franklin and 
Snow, 1989 ) . This mechanism, however, is not clinically as significant as the 
previous mechanisms. 
Mechanisms of bacterial resistance have been extensively reviewed ( Moyed , 1964; 
Gale et ai, 1981 ; Franklin, 1983; Bryan,1988; Williams and Moosdeen, 1986; 
Nord , 1986; Franklin and Snow, 1989 ) . 
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1.3. The Role of Metal Ions in the Microbial Cell 
1.3.1. Introduction 
All forms of life require metal ions for survival and growth. Heavy metals. such 
as cobalt (Co). copper (Cu) • iron (Fe). manganese (Mo) • Molybdenum (Mo) and 
Zinc (Zn) are usually less abundant in living cells than the lighter metals like calcium 
(Ca). magnesium (Mg). potassium (K) and sodium (Na) (Albert. 1985) . The 
importance of metal ions in microbial nutrition was first acknowledged back in the 
nineteenth century when Louis Pasteur found that the addition of ash was necessary for 
the growth of yeasts on a medium containing ammonium salts and sucrose ( Knight. 
1951) . It is now well established that metal ions play a fundamental role in the 
integrity. growth and metabolism of microbial cells. as well as their tolerance towards 
environmental factors . 
1.3.2. Role of metal ions in the inte&ffiy of the microbial cell 
Although metal ions that are required by micro-organisms serve mainly as activators 
or active groups of a variety of enzymes (Snell • 1957) • some play an essential role in 
the integrity of cellular structures. The bulk of bacterial magnesium (Mg2+) is 
associated with ribosomes and is needed for the preservation of the structure of 
ribosomes (Allen and Wong • 1986) . In addition. Mg2+ stabilises spheroplasts • 
suggesting its involvement in the integrity of the cellular membrane (Jasper and Silver. 
1977) . Calcium (Ca2+) is also involved in the integrity of bacterial cells as it stabilises 
cell wall structure by bridging carboxyl groups in peptidoglycan chains (Silver. 1977). 
Metal ions also play a significant role in the stability and integrity of nucleic acids. 
Wacker and Vallee (1959) showed that several metals including chromium (Cr) • 
manganese (Mo). nickel (Ni). iron (Fe) and zinc (Zn). were associated with RNA 
14 
from various biological sources. Their findings suggested that metals may play a role 
in the maintenance of the configuration of the RNA molecule by linking purine and / or 
pyrimidine bases through covalent bonds. Various mono- as well as divalent metal 
ions are also associated with bacterial DNA (Sigee and El-Masry , 1987) , and their 
role in the integrity and conformation of the DNA has also been studied ( Subirana , 
1987) . 
1.3.3. Role of metal ions in enzymes 
A metallo-enzyrne is that enzyme which retains stoichiometric, tightly bound, 
functional metal ions upon purification, in contrast to activated enzymes which require 
the addition of metal ions for activity ( Boyer et aI , 1964 ) . The list of 
metalloenzymes is probably large; some of these enzymes and their metallic 
components are listed in Table 1.3 . 
Table 1.3 Some known metallo-enzymes . 
Enzyme(s) Metal ion(s) References 
AlPase Mg,Ca Jasper and Silver (1977) 
a - Amylase Ca Silver (1977) 
RNA and DNA polyrnerases Zn Wu and Wu (1987) 
Wu and Chatterji (1983) 
Nitrogenase Fe Byers and Arceneaux (1977) 
Cytochromes Fe Coughlan (1971) 
Aldehyde oxidase Mo Rajagopalan (1987) 
Microbial Ureases Ni Hausinger (1987) 
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1.3.4. Regulation of secondary metabolism by metal ions 
In addition to their functions as coenzymes and stabilisers of cellular structures, 
some metals play a critical role in the regulation of biosynthesis of microbial metabolites 
such as toxins, vitamins and antibiotics. The quantity of zinc , generally, is critical for 
secondary metabolic processes in fungi and actinomycetes , whilst the concentration 
of manganese is important in species of Bacillus and the amount of iron is influential 
in other bacteria including the actinomycetes (Weinberg , 1982) . 
Many examples of the effects of iron on the biosynthesis of microbial metabolites 
are available as iron's role in microbial metabolism has received intensive attention over 
the years. Toxin production by Corynebacterium diphtheriae , for example, is greatly 
enhanced by low levels of iron in the medium (Coughlan, 1971). Similarly, iron-
deficiency in Candida species ( Goodwin, 1959) or Clostridium acetobutylicum 
( Hickey , 1945 ) results in increased production of riboflavin .The production of 
antibiotics, such as actinorubin by actinomycetes , chloramphenicol by Streptomyces 
venzuelae and penicillin by Penicillium chrysogenum is greatly enhanced by 
concentrations of iron greater than required for optimal growth (Weinberg, 1962). The 
production of other antibiotics, such as cblorotetracycline by Streptomyces 
aureofaciens , oxytetracycline by Streptomyces remosus and neomycin by 
Streptomycesfrudiae is ,however, reduced by higher concentrations of iron 
(Weinberg , 1962 ; Cougblan , 1971 ) . 
l.3.5. Bacterial response to iron-deficiency 
/ 
Iron is so essential for the viability of some micro;-organisms that in iron-restricted 
environments, they produce substances, known as siderophores , that have high 
affinity for iron (Fe3+) and which facilitates active iron uptake. A siderophore is 
defmed as a low-molecular-weight ( 500 - 1000 daltons ) virtually ferric specific 
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ligand, the biosynthesis of which is carefully regulated by iron and the function of 
which is to supply iron to the cell (Byers and Arceneaux, 1977 ; Neilands, 1981 ; 
Bagg and Neilands , 1987 ; Brown and Williams , 1985 ; Ankenbauer et al , 1988 ; 
Crosa , 1989; Martinez et al , 1990) .Although the majority of siderophores that have 
been isolated and identified are of bacterial origin, they are also produced by fungi 
under iron-deficiency conditions ( Holzberg and Artis , 1983 ) . Table 1.4 lists some 
micro-organisms and the siderophores they produce . 
In general, siderophores may be broadly classed, according to their chemical 
structure as either hydroxamates [-CO-N(O-)-] or phenolates - catecholates 
(Neilands , 1981) : 
R OH 
(I 
\ 
x ~ 11 I ~-C-R R=H,OH jX=O,N. 
Table 1.4 Some siderophores and their microbial origin (Neilands • 1981). 
Bacteria 
Enteric species 
Agrobacterium rumefaciens 
Pseudomonas species 
Bacillus megarerium 
Mycobacteria 
Actinomyces species 
Fungi 
Penicillia, AspegiIIi , 
Neurospora 
Rhodotorula species 
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Siderophore 
Enterobactin • aerobactin 
Agrobactin 
Pyochelin • pyoverdin , pseudobactin , 
ferribactin 
Schizokinen 
Mycobactins 
Ferrioxamines 
Ferrichromes,coprogen 
Rhodotorulic acid 
In addition to the production of siderophores , bacteria growing under iron-
restriction derepress the synthesis of several outer-membrane proteins, some of which 
serve as receptors for ferric-siderophores (Brown and Williams ,1985 ; Chart et al , 
1988) . 
The significance of siderophores as microbial virulence factors stems from the 
knowledge that the level of freely available iron in the healthy mammalian host is 
severly restricted ( Chart et al , 1988 ) . It follows that siderophores , with their 
exceptionally high affinity to iron , scavenge the minute amount of free iron available in 
the host during infection in order to maintain growth and viability. Outer-membrane 
proteins profIles of Pseudomona aeruginosa isolated, without subculturing , from the 
lungs of Cystic Fibrosis patients, were similar to the outer-membrane proteins profiles 
of the same organism grown in the iron-limited medium under laboratory conditions 
( Brown et aI, 1984) . This provided evidence that, in vivo, bacteria grew under 
iron-restricted conditions , and was further supported by similar observations on 
Klebsiella pneumoniae isolated from the urinary tract of infected patients ( Shand 
et al , 1985 ) . Such changes in the outer-membrane may also contribute to the 
resistance of Gram-negative bacteria to antibiotics ( and hence to chemotherapy) , since 
the outer-membrane serves as a barrier to permeation of antibiotics ( Nikaido , 1988 ) . 
Indeed, the resistance of Pseudomonas aeruginosa to penicillin G , of 
Staphylococcus aureus to phagocytosis and of Neisseria gono"hoeae to the 
bactericidal action of serum have all been enhanced by changes in outer-membrane- or 
surface-associated proteins provoked by iron-limitation ( Iohnson, 1985; Domingue 
etal, 1989). 
This microbial response to iron-restriction has potential therapeutic applications. 
Iron-regulated outer-membrane proteins may serve as possible vaccine components 
where the antibodies produced in response to such a vaccine would bind specifically to 
the outer-membrane proteins of the respective pathogen. Siderophores and their 
18 
semi-derivatives may prove useful as antibacterial agents probably acting by depriving 
bacteria of iron ( Brown, 1985 ) . 
Such is the significance of metal ions in the survival and growth of micro-
organisms, that organic compounds that are able to bind strongly to metal ions forming 
stable complexes exhibit antimicrobial action against many micro-organisms . The 
antimicrobial action of such compounds, known generally as chelating agents, is 
discussed in the next section. 
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1.4. The Antimicrobial Activity of Chelating Agents 
1.4.1. The Process of Chelation 
Chelating agents are metal-binding substances or 'ligands' . When a metal is 
gripped, in a ligand, between any of the elements nitrogen (N) , oxygen (0) , or 
sulphur (S) , a 'chelate' is formed in which the metal is more tightly bound than when it 
is not part of the ring (Alben , 1985) . The term 'chelate' was first used to describe this 
phenomenon by Morgan and Drew (1920), and is derived from the Greek word 
'chely' , the great claw. 
Chelating agents may be classified according to the number of donor atoms capable 
of combining with a metal atom. Thus, a chelating agent can be bidentate ( only two 
donor atoms available) , e.g. 8-hydroxyquinoline ; tridentate, e.g. terpyridine ; 
quadridentate , e.g. triethylenetetramine ; quinquedentate , e.g. tetraethylenepentamine ; 
or even sexadentate, e.g. ethylenediaminetetraacetic acid (EDTA) (MelIor, 1964). 
1.4.2. Stability of Metal-Chelates Complexes 
The stability of metal-chelates complexes depends on a variety of factors that have 
been discussed by Melior (1964) , namely: 
(1) The size of the ring formed; 5-membered ring chelates are generally more stable 
than 4- or 6-membered ring chelates . 
(2) Number of rings formed; chelating agents forming the greater number of chelate 
rings with a given metal , form the more stable complex compared to similar chelating 
agents. 
(3) For a series of closely related chelating agents, the greater the basic strength (PKa), 
the greater the stability of the metal chelate . 
(4) The steric hindrance arising from the process of chelation. 
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(5) Chelating agents with different donor atoms may form more stable complexes than 
if they had similar donor atoms . 
(6) Influence of the central metal atom; chelating agents have the following general 
preference for metal atoms ( Alben • 1985 ) : 
Fe3+ • Hg2+ 
Cu2+ • A13+ 
Ni2+ • Pb2+ 
Co2+ • Zn2+ 
Fe2+. Cd2+ 
Mn2+ 
Mg2+ 
Ca2+ 
Li+ 
Na+ 
K+ 
greatest avidity 
least avidity 
To quantify the stability of metal-chelates • stability constants (K) are used . These 
are constants governing the mass-action equilibrium between the ligand(s) and one ion 
of the metal (Albert • 1985) . Since one ion of the metal may bind with more than one 
ligand. more than one stability constant can be measured. thus. K J • K2 •...• Kn are 
stability constants for a I: I • 1:2 •...• 1: n (metal: ligand) chelates . The product of 
the individual constants is the cumulative stability constant B". where (n) is the number 
of individual constants multiplied to give B. The determination of stability constants 
has been discussed in detail by Albert and Serjeant (1984) . 
1.4.3. The Antimicrobial Activity of Chelating Agents 
Alben (1985) suggested two main mechanisms for the antimicrobial action of 
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chelating agents. A chelating agent may bind and remove an essential metal from the 
cell thus causing deficiency in this particular element or the inactivation of metal-
containing snuctures within the cell (e.g. enzymes) . Alternatively, a chelating agent 
may cause the imposition on the cell of metals in greater quantity ( or at a higer 
oxidation potential) than normal , and the complex of the chelating agent and the metal 
would then cause damage to various cell components. Two examples of these 
mechanisms, namely EDTA and 8-hydroxyquinoline, respectively, are discussed in 
the next two subsections. 
1.4.4. The Antimicrobial Action of Ethy1enediaminetetra-acetic acid ( EDTA ) 
The antimicrobial value of the EDTA has been reviewed ( Russell , 1971 ; 
Wilkinson, 1975 ; Hart, 1984) . Due to its low cost and toxicity, EDTA and other 
related compounds ( Fig.l.4 ) have been used in many pharmaceutical preparations 
( Hart , 1984 ) . EDTA is not normally considered as being an antibacterial compound 
in its own right ( Russell , 1971 ) , since it lacks broad-specnum antibacterial activity 
and does not achieve total bacteria! kill ( Hart , 1984 ) . However, it has a considerable 
value in microbiology since: (1) EDT A has a specific and potent antibacterial ( lytic) 
activity against Pseudomonas aeruginosa and (2) EDTA potentiates the antibacterial 
activity of a wide range of compounds against a wide range of micro-organisms , and 
in particular Gram-negative bacteria . These two characteristics of EDTA are discussed 
below. 
1.4.4.1. The Antibacterial Action of EDTA a~ainst fseu4mrumas aern~inosa 
Whilst investigating the lytic effects of the combination of lysozyme and EDTA 
against Gram-negative bacteria, Repaske (1958) noted that EDTA alone caused a 
significant lysis of cells of Pseudomonas aeruginosa in Tris ( Iris (hydroKymethyl) 
arninoethane ) buffer. Other organisms such as Escherichia coli and Azotobacter 
vinelandii were not lysed by EDTA alone (Repaske , 1958) . These observations 
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HOOCCH1 CH1COOH 
" ~ 
NCH1CH1N 
/ '" HOOCCHz CH1COOH 
(a) 
HOCH1CH z CHzCOOH 
'-... / 
NCHzCHzN 
/' '" HOOCCH1 CHzC 0 0 H 
(b) 
HOOCCHz CHzCOOH CH1COOH 
" / / NCH1CHzNCHzCH1N 
HOOCCHz/ ~ CHzC 00 H 
(c) 
Figure 1.4 (a) Ethylenediaminetetraacetic Acid ( EDTA ) 
(b) Hydroxyethylethylenediarninetriacetic Acid (HEEDTA) 
(c) Diethylenetriarninepentaacetic Acid (D1PA ) 
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were supported by Eagon and Carson (1965) , who also found that the metal ions 
Ca2+, Mg2+ and Zn2+ but not Mn2+ were chelated from the cells of Pseudomonas 
aeruginosa treated with EDT A . Ca2+ was the metal ion chelated in the greatest quantity 
from the cells and Mg2+ the least. Eagon and Carson (1965) concluded that divalent 
ions, and in particular calcium, are essential for the integrity of the cell walls of 
Pseudomonas aeruginosa , and that they may function to form cross-linkages between 
mucopeptide and non-mucopeptide components of the cell wall. EDTA, therefore , 
through its chelating action, extracts suffICient of such metal ions from the cell wall to 
cause the loss of cellular integrity and subsequently cell lysis . Other workers , 
however, have suggested that Mg2+ is the main target for chelation by EDT A in 
Pseudomonas aeruginosa , since equivalent concentrations of Mg2+ prevent EDTA 
action (Leive ,1968 ) . Indeed, cells of Pseudomonas aeruginosa whose cell walls are 
richest in Mg2+ compared to other strains of the same organism and which contain high 
quantities of Ca2+ (0.15%) and Mg2+ (0.2%) of the total ash content ( 7% of dry 
weight, Eagon et al , 1965 ) , were most sensitive to the lytic action of EDT A 
according to Haque and Russell (1974 , 1976) . It is probable that both Mg2+ and Ca2+ 
play a significant role in the integrity of the cell wall . Cells of Pseudomonas 
aeruginosa grown in minimal media deficient in either Mg2+ or Ca2+ were more 
resistant to EDTA than when grown in minimal media supplemented with these cations 
( Boggis et al , 1979 ; and Kenward et al , 1979 ) . 
In addition to its chelation of metal ions in the cell envelope of Pseudomonas 
aeruginosa , EDTA causes the release of 30 - 50 % of lipopolysaccharides from the 
outer-membrane, leading to further disintegration of the outer-membrane and cell 
envelope( Stinnett et al , 1973 ; Spicer and Spooner , 1974 ; Haque and Russell , 
1976 ; Matsushita et al , 1978 ; Rogers et al , 1969 ; Russell et al , 1987 ; Russell 
and Furr , 1987) . FUrthermore, it has been suggested that the lysis of cells of 
Pseudomonas aeruginosa by EDTA is due to the potentiation of autolysins , specific to 
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this organism (Leive, 1968). The various effects ofEDTA on Pseudomonas 
aeruginosa and other micr<rorganisms are summarized in Table 1.5 
Table 1.5 Summary of the Antimicrobial activity of EDT A (Russell , 1971 ) . 
Organisms 
Ps. aerugirwsa and other 
EDTA-sensitive Pseudomonatls 
EDTA-resistant Pseudomonads 
Colifonns 
Gram-positive bacteria, 
e.g. Staphylococcus aureus , 
Staphylococcus albus and 
M .. lysodeikticus 
EffectofEDTA 
1- Leakage of intracellular material , lysis 
( in sucrose, no leakage, spheroplast 
formation) . 
2- Release of lipopolysaccharides (LPS) . 
3- Increased sensitivity to other 
antibacterial agents . 
1- No leakage, lysis or release of LPS . 
1- Release of surface-bound enzymes. 
2- No lysis. Some release of LPS . 
3- Increased sensitivity to other 
antibacterial agents . 
1- No apparent effect. No increased 
sensitivity to other antibacterial agents. 
1.4.4.2. The Potentiation of other Antibacterial agents by EDT A 
MacGregor and Elliker ( 1958) reported that cells of Pseudomonas aeruginosa , 
resistant to alkyldimethylehtylbenzylammonium chloride, became sensitive following 
treatment with EDT A . It was concluded that quaternary ammonium gennicide resistant 
strains of Pseudomonas aeruginosa owe their resistance to their impenneability to this 
25 
class of compound, and that EDTA enhances cell pemeability by changing the outer-
membrane integrity by metal removal . 
Many examples of this synergy between EDT A and antibacterial agents followed . 
EDT A enhanced the activity of polymyxin B sulphate and chlorhexidine diacetate 
against Pseudomonas aeruginosa ( Brown and Richards , 1965 ) .This synergy was 
blocked by the presence of Mg2+ or Ca2+ in the medium, supporting the hypothesis 
that the potentiation action of EDT A is due to its chelation of these metal ions from the 
cell envelope. Synergy between EDTA and each of the antibiotics penicillin, 
ampicillin, tetracycline and chloramphenicol against Pseudomonas aeruginosa , 
Escherichia coli and Proteus mirabilis has also been observed (Weiser et al , 1968 ). 
EDT A potentiates the action of many other antibacterial agents, and some of these are 
summarized in Table 1.6 . 
In summary , this action of EDT A is generally believed to to be the result of the 
compound 'stripping' away a portion of the outer-membrane and cell wall of Gram-
negative organisms ( by chelating Mg2+ and Ca2+ ions normally responsible for outer-
membrane stability) . Tbis exposes the underlying cytoplasmic membrane and cell 
interior to attack by the other agent in the combination ( Denyer et al , 1985 ) . 
The most useful application ofEDTA has undoubtedly been in the area of 
preservation of pharmaceutical products against Gram-negative organisms, and in 
particular Pseudomonas aeruginosa (Hart, 1983,1984). The use ofEDTA with 
preservatives such as quaternary ammonium compounds, chlorhexidine , phenolics 
and esters of p-hydroxybenzoic acid is highly recommended and already applied 
(Hart, 1984). EDTA is also used to potentiate general-purpose antiseptics and 
disinfectants, and combinations ofEDTA and antibiotics have already been suggested 
for the treatment of surface infections ( Wilkinson , 1975 ) . 
At an appropriate concentration (2Omg / ml) , EDT A is an effective anticoagulant, 
and it has been suggested as a replacement for heparin to maintain the patency of the 
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lumen in central venous catheters. EDTA has the advantage over heparin of having 
inherent antibacterial activity against some problematic organisms in this area such as 
Staphylococcus epidennidis ( Root et al , 1988 ) . 
Table 1.6 Antimicrobial agents that show synergistic interaction with EDT A against 
bacteria. 
Antimicrobial Agents 
Quaternary Ammonium 
Compounds 
Polymyxin B , 
Benzalkonium chloride, 
Chlorhexidine 
Penicillin, Ampicillin , 
Tetracycline and 
Chloramphenicol 
Vancomycin 
Chloroxylenol 
Organisms 
Ps. aeruginosa 
Ps. aeruginosa 
E. coli, 
Ps. aeruginosa 
and Pr. mirabilis 
E. coli 
E. coli and 
Ps. aeruginosa 
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1.4.5. The Antimicrobial Mode of Action of Oxine ( 8-hydroxYQuinoline ) 
Oxine ( Fig.l.5a ) exhibits broad spectrum antimicrobial activity, though Gram-
positive bacteria are more sensitive than fungi which are more sensitive than Gram-
negative bacteria ( Frier, 1971 ) . The compound has found use as a preservative in 
topical cosmetic preparations , as a disinfectant and as an antiseptic ( Wallhausser , 
1984) . 
The mode of action of oxine against micro-organisms has been the subject of 
investigation for many years. The earliest repon linking the chelating properties of 
oxine to its antimicrobial activity is that by Zentmyer (1943) , who suggested that the 
antifungal action of oxine was due to its ability to chelate metal ions from enzymes and 
vitamins in microbial cells. This was based on the finding that oxine was inactive at 
low pH values at which the metal chelates dissolve and ionise . 
The significance of chelation in the antibacterial action of oxine was investigated 
more thoroughly by Alben and colleagues. Of seven possible isomeric mono-
hydroxquinolones , only oxine is capable of chelation and was shown to possess 
antibacterial activity (Albet et ai, 1947 ) . Using the Gram-positive organism, 
Staphylococcus aureus , it was shown that oxine per se has no antibacterial activity 
and that its toxicity is evident only in the presence of iron or copper, with iron being 
the more imponant for antibacterial action ( Rubbo et al , 1950 ) . The molar ratio of 
iron to oxine in the medium is also critical for the antibacterial action of that compound. 
In the presence of excess oxine , a 2: 1 oxine-iron complex (Fig.1.5b) is fonned in 
place of the 1:1 complex (Fig.1.5c). The 2:1 oxine-iron complex is more lipophilic 
than the 1: 1 complex and therefore penetrates the bacterial cell envelope more rapidly. 
Albert et al (1953) , however, suggested that the; fonner complex is actually devoid of 
antibacterial activity against Staphylococcus aureus , whilst the latter 1: 1 complex is 
the antibacterial species. They suggested that the 2: 1 oxine-iron complex will readily 
penetrate the bacterial cell but would then dissociate inside the cell to give the toxic 1: 1 
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complex (Rubbo et ai, 1950; Alben et al , 1953) , 
The actual mechanism of action of oxine at the molecular level ( specific targets etc,) 
remains unclear, but would appear to reside within the cytoplasmic membrane 
(Alben, 1985), The unsaturated 1:1 oxine-iron complex is believed to catalyse the 
oxidation, by atmospheric oxygen, of several vital cell constituents, panicularly 
mercapto-compounds such as dihydrolipoic acid, Such reactionsare greatly enhanced in 
the presence of traces of iron or copper and may lead to the production of highly 
damaging peroxide radicals ( '0-2 ) , These would initiate chain reactions causing 
widespread destruction ( Alben , 1985 ) , 
This co-operative effect between oxine and iron is antagonised strongly by trace 
amounts of cobalt (Rubbo et al , 1950 ; Albert et al , 1953 ) , This antagonism could 
not be simply explained on the basis of competition between cobalt and iron for the 
chelating site in oxine , since the stability constant of the oxine-iron complex is higher 
than that of the oxine-cobalt complex ( Alben , 1985 ) , Instead, cobalt is believed to 
act as a chain breaker of the oxidative chain reaction induced by the oxine-iron complex 
( Dainton , 1966 ; Alben ,1985 ) , 
The antifungal action of oxine has also been investigated, Both oxine and the 
oxine-copper complex are fungicidal with the latter being more toxic ( Powell , 1946 ; 
Sijpesteijn et al , 1957 ) , This is in contrast to the observations on the action of oxine 
and its iron complex against Gram-positive organisms discussed above ( Albert et al , 
1947 ; Rubbo et ai, 1950 ; Albert , 1953 ) , Copper 8-quinolinolate is also more toxic 
to fungi than other metal-oxine chelates such as magnesium-, iron- and zinc 8-
quinolinolates ( Mason, 1948 ) , Zentmyer et al (1960) observed that amino acids 
such as cysteine, histidine, tryptophan and casamino acids reversed oxine toxicity 
against spores of Aspergillus roger, They suggested that oxine enters the cell as the 
copper-oxine complex, and that amino acids of the cell remove copper from the 
complex releasing oxine in situ, Whilst free copper poisons amino acids, proteins and 
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enzymes. free oxine sequesters prosthetic trace metals such as iron and zinc from 
enzymes and systems that require them for biological activity . 
In more recent studies. aliphatic thiol-containing compounds ( such as cysteine. 
glutathione. dithioerythritol and dithiothreitol ) and DL-a-lipoic acid were found to 
reverse the fungitoxic activity of oxine but not that of the copper chelate ( Gershon 
et al • 1975) . It has been suggested that oxine itself interferes with the biosynthesis of 
lipoic acid ( a cofactor for oxidative enzymes such as pyruvate oxidase; Guirard and 
Snell • 1962 ) • and that the mechanism of fungitoxicity of the oxine-copper chelate is 
different from that of free oxine ( Gershon and Shanks. 1981 ; Gershon et al • 
1985) . 
The antimicrobial action of oxine has been reviewed ( Weinberg • 1957 ; Albert • 
1982. 1985) . 
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1.5. Sodium and Zinc Pyrithione 
1.5 1. History 
Pyrithione (2-mercaptopyridine-N-oxide), also known as omadine, was first 
synthesized by Shaw et aI (1950). In the preparation, 2-bromopyridine was convened 
to its N-oxide by oxidation with m-chloroperoxybenzoic acid or peracetic acid. 
Treatment of the N-oxide with sodium sulphide or sodium hydrosulphide under mild 
conditions gave pyrithione (Fig.l.6a) or sodium pyrithione, respecitvely . Zinc 
pyrithione (Fig1.6b) is prepared from sodium pyrithione using a water soluble zinc 
salt . Pyrithione was prepared during the search for analogues of the naturally occuring 
antibiotic, aspergillic acid (Lott and Shaw, 1949; Shaw et ai, 1950). 
The first patent, covering the composition and manufacture of pyrithione and its 
sodium salt, was granted in 1954 (Shaw and Bemstein, 1954). A second patent 
followed, which covered the heavy metal derivatives of pyrithione (Bemstein and 
Losee, 1957). The antidandruff properties of zinc pyrithione were discovered in the 
1960's and patents were issued covering its use in antidandruff shampoos and 
preparations (Karsten et ai, 1966; Karsten and Taylor, 1968). 
1.5.2. General propenies 
1.5.2.1 Physical propenies 
The physical and chemical properties of sodium and zinc pyrithion have been 
reviewed previously (Olin Corporation, 1983; Nelson and Hyde, 1981; Hyde and 
Nelson, 1984). 
Sodium pyrithione is a salt and hence is highly soluble in water (53%w/w at 25°C), 
whereas zinc pyrithione is a lipophillic chelate barely soluble in water (0.0015% w/wat 
25°C). Both compounds absorb ultraviolet light; typically zinc pyrithione absorbs at 
244, 275 and 320nm in methanol and 239, 268 and 320nm in water. Sodium 
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pyrithione absorbs at 248, 290 and 345nm in methanol and at 243,281 and 322nm in 
water (Olin Corporation, 1983). 
1.5.2.2 Chemical pr<werties 
Pyrithione is a weak acid with a pKa value of 4.7 (Chandler and Segel, 1978). In 
solution, pyrithione exists in two tautometric forms, the thiol and the thione as shown 
in Figure 1.7 (Shaw, 1949; Shaw et ai, 1950; Jones and Katritzky, 1960). The thione 
form prevails at or below pH 3, the thiol form appears as the pH is raised with the 
equivalence point being around 7.6. 
Pyrithione is oxidised by peroxides to the disulphide which under alkaline 
conditions produces sulphinic acid, further oxidation yields sulphonic acid . In the 
presence of reducing agents, pyrithione is converted to 2-mercaptopyridine. Both 
sulpbinic and sulphonic acids are microbiologically inactive and 2-mercaptopyridine is 
less active than pyrithione itself. 
One of the most important properties of pyrithione is its ability to chelate metal 
ions. Pyrithione forms complexes with almost all metal ions under almost any 
conditions, with many of these complexes being coloured. Transchelation will also 
occur, for example, iron, copper, mercury and silver will replace zinc in zinc pyrithione 
because the stability constant of zinc pyrithione is less than that of the other four metal-
pyrithione complexes (Olin Corporation, 1983). 
1.5.2.3 Stability 
Sodium and zinc pyrithione are generally stable over the range pH 4.5 to 9.5 , 
though the recommended pH range for the use of sodium pyrithione is 7 to 10 . Both 
compounds are stable at 100°C for at least 120 h and there is no loss of biological 
activity of aqueous solutions of sodium pyrithione after storage at 4Q°C for 3 months 
(Nelson and Hyde, 1981). 
Pyrithione undergoes rapid photodegeneration (Evans et ai, 1975 ; Neihof et 
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al,1979). After 5 to 10 hours exposure to light of an aqueous solution at l00ppm, ten 
fold increases in bioassay concentrations were necessary to equal toxicities of the 
unirradiated solution. Wave lenghts of 320 to 355nm were most effective in producing 
photodegradation. 
1.5.3 Analytical Methods 
Several techniques have been developed for the assay of pyrithione and its metal 
complexes, including polarography (Krivis et aI, 1963; Krivis and Gazda, 1969), and 
thin-layer chromatography (1LC ; chloroform: methanol (49: I) ; Seymour and Bailey, 
1981). Polarographic analysis ofpyrithiones is specific and widely used, whereas 1LC 
analysis requires special conditions to minimise photodecomposition and chemical 
interaction between the pyrithione and the materials in the thin-layer plate. A simple 
colorimetric method has been developed and involves reacting pyrithione with ferric 
ammonium sulphate under acidic conditions to yield the pyrithione-Fe (3:1) complex. 
This complex absorbs light at 61Onm. 
1.5.4 Antimicrobial and Mode of Action of Pyrithione 
The antimicrobial activity of pyrithione was observed when it was first synthesized 
(Shaw et aI, 1950). Pyrithione inhibited the growth of both Gram-positive and Gram-
negative bacteria with the latter being comparatively less sensitive 10 the drug. In 
addition, sodium pyrithione showed powerful anti-fungal activity (Pansy et al, 1953). 
In spite of this, and the wide use of pyrithione as an antidandruff agent as well as a 
general preservative, only a few attempts have been made since its discovery to fully 
understand the mode of action of this compound. 
Alben et al (1956) suggested that pyrithione had an identical mode of action to that 
of oxine (8-hydroxyquinoline), since the former is rapidly bactericidal, inactive in the 
absence of traces of iron, inactive in the presence of iron if cobalt was added , and 
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inactive in concentrated solution. The I: I complex with iron would thus be the toxic 
species whilst the 2: I complex would be more Jipophillic and may penetrate bacterial 
cells easier, releasing the I: I complex intracellularly. The I: 1 complex is highly 
reactive producing, within cells, various peroxide and superoxide radicals causing 
damage and cell death (AI ben, 1985). The antifungal activity of pyrithione, however, 
was attributed to the copper complex rather than the iron complex, following the 
observation that both the 1: 1 and the 1:2 copper-pyrithione complexes are equally toxic 
to the fungus Aspergillus niger (Sijpesteijn et ai, 1957). The bactericidal activity of 
zinc pyrithione is quenched by sodium thioglycollate, suggesting that pyrithione acts by 
oxidising free thiol groups (-SH) in proteins within the cell (Elkhouly, 1974). Although 
the concentration of sodium thioglycollate used was 25-50 (%w/v) times the minimum 
inhibitory concentration of zine pyrithione against Staphylococcus aureus in the study, 
such a mechanism of action cannot be ruled out In a study of the relationship of 
structure to antimicrobial activity of a series of pyrithione-N-oxides, the most active 
compounds were those in which the 2 position on the pyridine ring was substituted by 
a sulphur-containing group wherein the sulphur atom is attached directly to the ring 
(Leonard et ai, 1956). 
The structural similarity between pyrithione and, nicotinic acid and vitamin B6 , 
suggests the possibility that pyrithione acts as an antimetabolite (Cooney, 1969). 
However, no experimental evidence has been provided to suppon this hypothesis. 
Another possibility is that pyrithione chelates metal cofactors of various enzymes. 
Indeed, pyrithione does inhibit the zinc-requiring enzyme alcohol dehydrogenase 
(Cotton, 1963). 
Pyrithione has been shown to inhibit membrane transpon processes in fungi 
(Chandler and Segel, 1978). Investigations into the mode of action of pyrithione 
against Penicillium crysogenurn and P. notatum suggest that pyrithione acts as a 
proton conductor whereby the unionised molecule diffuses across the cell membrane 
and ionises intracellularly thereby collapsing a transmembrane pH driving force. This 
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also excludes the possibility that the main sites of action of pyrithione are the disulphide 
bonds within proteins. Pyrithione also inhibited in vivo protein synthesis and caused a 
reduction in intracellular A 1P levels in Penicillium; the thiol and N-oxide groups in 
the molecule were again found necessary for membrane activity. 
1.5.5. Toxicity of Pyrithione 
The toxicity of pyrithione has been reviewed (Black and Howes, 1978). The data 
on acute toxicity of some pyrithiones suggests that the metal complexes are more toxic 
than pyrithione itself, which in turn is more toxic than the sodium salt, when they are 
given orally or intraperitoneally. 
The effects of pyrithione on mammalian cells have been investigated both in vivo 
and in vitro, and various results have been reported. lmokawa and Okamoto (1983) 
suggested that zinc pyrithione acted primarily by reversibly inhibiting DNA synthesis in 
human skin cells in vitro, whilst RNA and protein synthesis were uninhibited. In 
comparison Gibson and colleagues (1985a) showed that zinc pyrithione had a clear 
effect on human cells, and that DNA, RNA and protein synthesis were all affected. The 
relatively low toxicity of zinc pyrithione when applied in vivo to the skin may be due 
to its inability to pass through the epidermis in high concentrations (Gibson et ai, 
1985b). Studies using human leukaemic myeloid cell lines have also shown pyrithione 
to have cytotoxic effects, including inhibition of DNA and protein synthesis, leading to 
cell death (Kontoghiorghes et ai, 1986a and b). Such DNA inhibitory effects were also 
reported by Fotsbeck et al (1987) and were found to be partially reversed in the 
presence of iron. 
1.5.6. The Pharmaceutical Value of Pyrithiones 
Pyrithione, as the zinc complex, is used wotldwide as a very successful anti-
dandruff agent The mechanism by which zinc pyrithione reduces dandruff was and 
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still is a matter of debate. Dandruff is excessive, clinically non-inflammatory scaling of 
the scalp (Kligman et al, 1976). In the great majority of cases diagnosis can be made 
almost instantly by simply inspecting and scratching the scalp surface. The idea that 
micro-organisms in general and Pityrosporum ovale in particular, incite or contribute 
to the production of dandruff dates back to the last century (Leyden et al,I976). The 
hypothesis explaining the microbial involvement in dandruff is that P. ovale can lyse 
sebum triglycerides to release fatty acids, some of which may irritate and produce 
scaling (Van Abbe, 1964). Supporters of this theory rely on the evidence the counts of 
P. ovale in subjects with dandruff are higher than those in healthy subjects (Kligman 
et aI, 1976). The suppression of dandruff by zinc pyrithione is also accompanied by a 
reduction in P. ovale counts (Imokawa et aI, 1982) as well as yeast micro-organisms 
in general (Marks et aI, 1985). 
In contrast, other workers believe that the higher incidence of P. ovale in the scalp 
of people with dandruff is due to the increase in surface area and nutrients for growth 
provided by the scaling process (Kligman et al,1976) . They suggest that the increased 
number of scalp micro-organisms found in dandruff occurs as a secondary event, and 
that micro-organisms play no primary role in the pathogenesis of dandruff (Leyden et 
al,1976). 
Antidandruff agents such as ~c pyDthione and selinium sulphide may thus act 
cytotstatically, slowing down the epidermal proliferative activity which leads to the 
scaling and dandruff (Plewig and Ligman, 1969). However Pearse and co-workers 
(1985) found that zinc pyrithione had no effect on epidennal renewal in normal human 
skin in vivo. 
The question of microbial involvement in dandruff remains, therefore, unresolved 
( Van Abbe, 1986 ). The importance of micro-organisms and particularly P. ovale in 
dandruff is, however, so deeply entrenched in theories of causation that the search for 
new antidandruff agents often utilizes an in vivo screen against P .ovale (Kligman et 
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ai, 1976). Zinc pyrithione apparently entered the channels of commerce via this route, 
and patents covering formulations of antidandruff shampoos containing zinc pyrithione 
are still being granted . 
1.6. Aims of Project 
To investigate the effects of pyrithione on the growth and survival of the Gram-
negative organism Klebsiella pneumoniae , as well as this organism's ability to 
develop resistance to pyrithione . The project also aims at examining the effects of 
pyrithione on some essential metabolic processes in KI. pneumoniae . Other organisms 
are included in the study for comparative purposes. It is hoped that this study will 
improve our understanding of the nature of drug-cell interactions in aid of the 
contineous search for improved antimicrobial agents. 
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1. General 
2.1.1. Micro-organisms 
The following micro-organisms were used in this study: 
Pseudomonas aeruginosa NCfC 6749 ,Klebsiella pneumoniae (subspecies 
pneumoniae ,NCm 8267) , Bacillus licheniformis NCIB 6346 , Bacillus 
licheniformis NCfC 1097 ,Bacillus cereus LUT 11755 ,Bacillus subtilis NCm 
3610, Bacillus megaterium NCm 8291 , Escherichia coli NCfC 9001 ,Salmonella 
abony NCfC 6017 , Serratia marcescens NCfC l377 , Mycobacterium phlei 
NCfC 8151 , Proteus vulgaris NCm 8067 , Staphylococcus aureus NCIB 8625 , 
Candida albicans NCYC 597 , Candida albicans NCYC l363 , Candida albicans 
NCYC 1466, Candida albicans A39 (Boots strain), Saccharomyces cerevisiae 
NCYC 345, Saccharomyces cerevisiae NCYC 975 and Debaryomyces hansenii 
NCYC8. 
2.1.2. Growth Media 
(1) Nutrient Broth (NB) containing: 
grams / litre group 
Lab-Lemco (Oxoid , Code L29) 10 I 
NeutraIised bacteriological peptone 
(Oxoid, Code L34) 10 I 
Sodium chloride 5 I 
(2) Chemically defined medium (CDM) containing: 
grams / litre group 
D-Glucose 10 2 
K2HP04 10 3 
KH2P04 5 3 
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Chemically defined medium (continued) grams / litre group 
~CI 2.5 4 
KN03 0.5 4 
Na2S04 0.5 4 
MgS04·7H2O 0.05 4 
FeCI3 0.005 5 
CaCI2 0.0025 5 
MnCI2.4H2O 0.005 5 
DL-methionine 0.5 6 
DL-aspartic acid 0.5 6 
L-proline 0.5 6 
biotin 0.0002 7 
Group I nutrients ( Nutrient Broth) were dissolved in distilled water (final volume 
I litre) and sterilised by autoclaving (121 0 C , 151b per square inch) for 15 minutes. 
Groups 2, 3 and 4 chemicals were dissolved in 700 , lOO and lOOm! of distilled water 
respectively, and sterilised by autoclaving . Group 6 chemicals were dissolved in 
lOOm! of distilled water and sterilised by filtration through Whatman membrane filters 
( pore size 0.45Ilm). Groups 2,3,4 and 6 were then mixed aseptically. Concentrated 
solutions of groups 5 
( FeCI3 ' 1.25% ; MnCI2.4H20, 1.25% ; CaCI2 ' 0.625% w/v ) and 7 (0.2% w/v) 
were prepared in distilled water and sterilised by membrane filtration as above , and 
small volumes (0.4 ml from group 5 ; ! ml from group 7) from each concentrate were 
added to the medium to give the required concentrations. 
When required, agar no. I (Oxoid, Code No. L1!) was added to nutrient broth 
(NB) at 1.5% (w/v) before sterilisation to give nutrient agar. Agar was added at 
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1.5% (w/v) to group 2 before sterilisation 'to give chemically defined medium agar 
(COMA). The final pH of either media was adjusted to 7.00± 0.2. 
2.1.3. Antimicrobial agents and related compounds 
The following compounds were used : 
(1) Sodium pyrithione (2-mercaptopyridine -N -oxide; sodium salt), Sigma Chemical 
Company LTD., Poole, Dorset, UK. 
(2) Diaminoethanetetraacetic acid, sodium salt (EDTA) , Fisons Pharmaceuticals, 
Loughborough, U.K. 
(3) 8-Hydroxquinoline (Fisons). 
(4) Ampicillin, sodium salt (Sigma). 
(5) 2- Mercaptopyridine (MP ; Sigma). 
(6) 2- Mercaptopyrimidine (MPY ; Sigma). 
(7) 2- Mercaptonicotinic acid (MNA ; Sigma). 
(8) 3- Hydroxy -2- mercaptopyridine (HMP ; Sigma). 
(9) Rifampicin; Sigma . 
2.1.4. Radiolabelled compounds 
The following radiolabelled compounds were purchased from Amersham 
International, Cardiff, U.K. : 
(I) (1-14C) Glycine (specific activity 58 mCi/mmole). 
(2) (2-14C) Thymidine (specific activity 53 mCilmmole). 
(3) (2-14C) Uridine (specific activity 52 mCi/mmole). 
(4) [a_32p] UTP (specific activity 800 Cilmmole). 
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2.1.5. Nucleotides and other chemicals 
(1) ATP, lithiwn salt ( 100 mmolell; pH 7; Boehringer Mannheirn). 
(2) CfP , lithium salt ( 100 mmole/l ; pH 7 ; Boehringer Mannheirn ) . 
(3) GTP , lithiwn salt ( 100 mmolell ; pH 7 ; Boehringer Mannheim ) . 
(4) UTP , lithiwn salt ( 100 mmole/l ; pH 7; Boehringer Mannheim) . 
(5) Salmon sperm DNA ( lOmg/ml ; Sigma) . 
(6) Tris (2-amino-2-(hydroxymethyl)-1,3-propandiol); Molecular Biology Grade; 
Boehringer Mannheim . 
(7) tRNA from Escherichia coli MRE600 ( RNAse negative; Boehringer Mannheim). 
(8) B-Mercaptoethanol ( Sigma) . 
2.1.6. Enzymes 
(1) RNA Polymerase (EC 2.7.7.6.; 2500units / rnI) from Escherichia coli MRE600; 
Boehringer Mannheim . 
All other chemicals were of general laboratory grade, unless stated otherwise . 
2.2. Experimental 
2.2.1. Sterilisation methods 
(1) Autoclave; at 121°C and 15 pounds per square inch for 15 minutes. 
(2) Membrane-filtration, using Whatman cellulose nitrate membrane filters with pore 
size of 0.4511m . 
(3) Dry sterilisation in an oven at 160°C for 1 hour. 
2.2.2. Maintenance of cultures 
All master cultures were maintained on both NA and CDMA slopes at 4°C in the 
dark. Organisms for routine experimental use were maintained by daily subculture on 
NAorCDMA. 
2.2.3. Preparation of standard cell suspension 
Isolated colonies (CDMA) oftest orgarnisms were grown in 50 m1 of fresh CDM 
in a Gallenkamp orbital incubator (37°C, 90 rpm) . After 12 hours, cells were 
harvested by centrifugation ( Mistral6L centifuge ) at 4000 rpm for 15 minutes, and 
resuspended in 50 m1 fresh CDM (37°C) . This suspension was then used for further 
experimental work. In general, all suspensions for experimental use were used within 
30 minutes of preparation. 
, 
2.2.4. Determination of the minimum inhibitOlY concentrations CMICs) 
The tube dilution method was used throughout Serial two-fold dilutions of the 
antimicrobial agent (or related compound) were prepared in 5 m1 volumes of liquid 
medium (NB) in universal bottles. These were inoculated with 30 III of an overnight 
( 12-16 hours, 37°C, NB) culture for bacteria and C. albicans ,48 hours culture for 
S. cerevisiae (30°C) and 48 hours culture for D. hansenii (20°C). All tubes were then 
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incubated at the appropriate temperature. The MIC was recorder as the lowest 
concentration of the test compound that inhibited growth (visible turbidity) of the 
organism after 24 hr incubation. 
The MICs of sodium pyrithione were determined against all organisms in nutrient 
broth and additionally against KI. pnewnoniae ,B. licheniformis NCIB 6346 , 
Ps. aeruginosa NCfC 6749, E. coli NCfC 9001 and C. albicans NCYC 597 in 
CDM . The MICs of other antimicrobial compounds were determined against these 
latter organisms were detemiined in CDM only. 
2.2.5. Influence of sodium pyrithione on the growth rate of micro-organisms 
The effect of pyrithione on microbial growth was studied using Kl. pnewnoniae , 
B. licheniformis NCm 6346 and C. albicans NCYC 597 . Standard cell suspensions 
of each organism were prepared as described in section 2.2.3. , and used tn inoculate 
fresh lOOml batches of CDM containing various concentrations of pyrithione in 250ml 
conical flasks. Cultures were incubated (37°C, 90 rpm) in a Gallenkamp orbital 
incubator and the optical densities measured using a Pye-Unicam SP500, series 2 
spectrophotometer (650 nm , 1 cm path) at various times. 
2.2.6. Effects of rechallenge on the growth rate of micro-organisms 
Preliminary experiments indicated that bacterial culture re-growth could occur at 
low pyrithione concentrations. This effect was investigated further as follows: 
Standard cell suspensions of either KI. pnewnoniae or B. licheniformis NCIB 6346 
were used to inoculate 6 x 100 m1 batches ofCDM containing various concentrations of 
pyrithione in 250 m1 conical flasks. These were incubated in the orbital incubator as 
described above, and measurements of optical density were taken at set time intervals. 
When bacterial cultures had reached an optical density of approximately 0.4 , 
0.1- 0.5 m1 of a drug concentrate in CDM was added to re-establish the drug 
concentration at levels at least equivalent to that present initially. Optical density 
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readings were recommenced after the re-addition of pyrithione .C. albicans NCYC 5fJ7 
culnrres were treated similarly, but pyritJiione was re-added after a fixed time interval 
to cultures instead of at a fixed optical density . 
In addition, to observe the effects of cell density on pyrithione effectivenes , 
duplicate cultures of all three organisms were grown as previously described but in 
the absence of pyrithione . When each culture was in (approximately) the 
mid-exponential phase, pyrithione was added using a drug-concentrate, and 
incubation continued with optical density monitoring as before . 
2.2.7.lnfluence of pyrithione on culture viability 
Standard cell suspensions of either KI. pneumoniae or C. albicans NCYC 597 
were used to inoculate fresh lOOmJ batches of CDM in 250 ml conical flasks containing 
various concentrations of pyrithione .Cultures were incubated as before (37°C, 90 
rpm) , and at set time intervals, 1 ml samples were withdrawn and diluted into a series 
of 9 ml volumes of sterile physiological saline (0.85% (w/v) NaCl) . The viability of 
the cells was assessed using the method of Miles and Misra (1938) , where 20~ 
aliquots were transferred from suitable dilutions onto the surface of surface dried 
nutrient agar plates. Plates were incubated at 37°C for 12-18 hr and colonies counted 
2.2.8. Cell size distribution of division-inhibited (ampicillin) cells of KI pneurooniae 
growing in the presence of pyrithione 
A method based on that devised by Rye and Wiseman (1968a) was used . 
Preliminary experimentation had established that Kl. pneumoniae would grow at an 
uninhibited rate, but without dividing, in CDM containing 50Jlg / ml ampicillin. 
Growing batch cultures (100mJ CDM) of Kl. pneumoniae were prepared as described 
above containing 50 Ilg / ml ampicillin and , in addition, 2.0 Ilg / ml pyrithione 
representing approximately 40% of the minimum inhibitory concentration (MIC) as 
determined by the tube dilution. Control cultures containing cells in CDM alone and in 
46 
CDM containing 50llg / m! ampicillin were 3Iso prepared. All cultures incubated at 
370 C and 90 rpm and Samples (1-5 m!) were removed from each culture at various 
times. Cells were collected from each sample by membrane filtration ( 0.45jlm 
Whatman cellulose nitrate membrane filters ) , and resuspended in Isoton containing 
0.2% fonnaldehyde . These suspensions were then analysed for size distribution using 
a coulter counter (Model TA 11 ) fitted with a 30Jlffi size tube . 
2.2.9. Interaction of EDT A with pvrithione 
2.2.9.1. A gar diffusion 
The method of Maccacaro (1961) was used. Whatman No.1 filter paper strips 
(Ix4 cm) were prepared and dry-sterilised as described in section 2.2.1 .. Strips were 
soaked in EDT A solution (0.1 % or 1.0% (w/v)) for 2-3 hours. A strip soaked with 
pyrithione (0.001 % or 0.1 % (w/v)) was placed on the surface of a CDMA (15m!) plate 
seeded with Kl. pneumoniae , B. icheniformis NCIB 6346 or C. albicans NCYC 
597 . Another strip soaked in EDT A was placed at right angles to the first strip, with 
the ends overlapping. Plates were incubated at 370C for 24-48 hours . 
2.2.9.2. Influence ofEDTA on pyrithione induced changes in growth rate 
Test organisms Kl. pneumoniae , B.licheniformis NCm 6346 and C. albicans 
NCYC 597 were grown, as before, in the presence and absence of pyrithione 
and / or EDTA . In each case, the concentrations were selected to be sub-inhibitory. 
Growth was monitored by optical density measurements ( 650 nm, 1 cm path) at 
various times . 
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2.2.10. Interaction of pyrithione with metal ions and 8-hYdroxyquinoline 
The agar diffusion method was used as described above (section 2.2.9.1.) . Solutions 
(0.01 % (w/v» of metal ions were prepared using the following water-soluble salts: 
MgS04.7H20 , CaCl2 ' FeCl3 ' MnC12.4H20 and ZnCI2. All three organisms 
Kl. pnewnoniae , B. licheniformis NCIB 6346 and C. albicans NCYC 597 , and 
both CDMA and nutrient agar seeded plates were used . The same method was used to 
assess the interaction between 8-hydroxyquinoline and pyrithione against all three 
organisms in both NA and CDMA . 
2.2.11. Influence of 8-hYdroxyquinoline on the growth of micro-organisms 
The effect of 8-hydroxyquinoline on the growth of Kl. pnewnoniae , 
B.licheniformis NCIB 6346 and C. albicans NCYC 597 was investigated in CDM. 
The growth of B. licheniformis and C. albicans was followed by measuring the 
optical density (650 nm , 1 cm path) , while the growth of Kt. pnewnoniae was 
assessed using the viable count method described in section 2.2.6. since precipitation 
interfered with optical density measurements. 
2.2.12. Influence of pyrithione on the uptake of radiolabelled substmtes by 
Kt. pneumonjae and B lichenjformjs NCIB 6346 
A method based on that outlined by Douglas and Freer (1982 a,b) was used . Batch 
cultures (4x50 ml CDM) of the test organism were prepared and shake incubated (90 
rpm in a Gallenkamp orbital shaker at 37° C) for 60 minutes. Approximately 0.2 IlCi 
of either 14C-thyrnidine , 14C-uridine or 14C-glycine (specific activity approximately 
5mCilmmole) was added to each flask , and incubation continued. After 3-4 minutes, 
pyrithione was added , as a concentrated solution , to three flasks to give final 
concentrations of 1,2.5 and 5.0 Ilg/ml in the case of Kl. pneumoniae and 0.01, 0.025 
and 0.05 Ilg/ml in the case of B. licheniformis . An equal volume of sterile distilled 
water was added to the fourth (control) flask , and incubation re-commenced . Samples 
(1 ml) were taken appropriate time intervals up to 30 or 60 minutes after the addition of 
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the radiolabelled substtates . The samples were added to 5 ml volumes of ice-cold 10% 
trichloroacetic acid (TCA), and mixed vigorously. Such mixtures were maintained at 
40 C for 30 minutes and then filtered through 0.451J.Ill Whatman cellulose nitrate 
membrane filters. Filters were washed twice with cold TCA before transfer to 
scintillation vials containing 10 ml of liquid scintillant (Ecosint) . The radioactivity 
present in each vial was measured using a Philips P4700 scintillation counter. 
In addition, the incorporation of radiolabelled thymidine, uridine and glycine was 
followed in a culture of Kl. pneumoniae incubated for a long period of time (in the 
presence of pyrithione ( 2.51lg/ml ) ) , which allowed the re-establishment of 
logarithmic growth . 
2.2.13. Effect of pvrithione on RNA polymerase activity in vitro . 
The method used was based on that of Chamberlin and Berg ( 1962 ) . A standard 
assay mix ( SAM ) was prepared containing: 1.17ml H20; 0.4 ml IM Tris.HCl ( pH 
7.8); 0.1 mllM MgC12; 0.08 ml of each of 50mM ATP, CTP, GTP and UTP; 12111 
B-mercaptoethanol . Three reaction mixtures ( RM ) were prepared ( at 4°C) in a l.5ml 
microfuge tube as follows: 
volume <Ill) 
Comoonent RMI RM2 RM3 
SAM 20 20 20 
DNA (salmon sperm; 5 5 5 
IOmg/ml) 
40IlCi [a_32p] UTP I I I 
pyrithione ( 25OIlg/ml) 0 0 1: 
Rifampicin ( Img/ml) 0 I 0 
RNA polymerase 2 2 2 
( 2500 units/ml ) 
Total volume (Ill) lOO lOO ·100 
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The tubes were incubated at 37°C for 20 minutes followed by storage on ice (4°C) 
for 30 minutes. To assay the incorporation of [a-32P1UTP , 2 III from each rection 
mixture was added to ice-cold solution containing 47J.1l H20, 12111 of 50% (w/v) TCA 
and 2111 of 2Omg/ml ( in H20) tRNA . The mixture was stored at 4°C for 15 minutes, 
after which they were filtered through Whatman GF/C glass microfibre filters and 
washed once with 10 ml of ice-cold 10% TCA and once with 10 ml of ice-cold ethanol 
. Filters were transferred into scintillation vials and counted in a Philips P4700 
scintillation counter. 
2.2.14. Some aspects of the adaptation of Kl, pneumoniae to pyrithione 
2.2.14.1. Determination of the MIC of pyrithione against control and pyrithione-treated 
~ 
Batch culture (100 ml CDM) of Kl. pneU11Wniae was prepared and shaken 
incubated (37°C, 90 rev. per minute) for 24 hours. The MIC ofpyrithione was 
assessed against this culture in CDM as described above ( section 2.2.4. ) , using the 
tube dilution method; the culture was used to inoculate 2x100 ml CDM batches to be 
labelled A and B respectively. Culture A contained no pyrithione whilst culture B 
contained 5.01lg / ml pyrihtione . A and B were incubated as described above. After 24 
hours, the MIC of pyrithione was assessed against samples of cells taken from A and 
B . A was then subcultured into drug-free CDM (100 ml) , whereas B was subcultured 
into both pyrithione-free (labelled C) and pyrithione-containing ( 5.0J.1g/ml ; labelled D) 
CDM. 
Cultures A,C and D were incubated and repeatedly subcultured into their respective 
media ( with or without pyrithione ) , every 24 hours for 7 days. The MIC of 
pyrithione was assessed and recorded for sample organisms from each culture every 24 
hours prior to sub-culturing. 
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2.2.14.2. Influence of Pyrithione on the growth of Pyrithione-treated cells of 
Kl. pneumoniae 
Using a standard cell suspension of KI. pneumoniae (section 2.2.3.) , a 100ml 
batch of CDM containing 5.0Jlg/ml pyrithione was inoculated ( Iml ) and incubated 
(37°C, 90 rpm) for 24h . This culture was then used to inoculate ( to give an 
O.D.65Orun of approximately 0.1 ) 6xlOOml batches of fresh CDM containing 0.0 , 
1.0 , 2.0 , 3.0 ,4.0 and 5.0 Jlg/ml pyrithione . Incubation followed (37°C ,90rpm) and 
growth was monitored using optical density measurements ( 650nm , 1cm path) . 
2.2.14.3. Cross-resistance of pyrithione-treated cells of KI pneumoniae and 
B ljcheniform;s NCIB 6346 
Inocula from either organism were grown in 2x100 ml of fresh CDM containing 
0.0 and 5.0 Jlg/ml pyrithione in the case of KI. pneumoniae and 0.0 and 0.05Jlg/ml of 
the drug in the case of B. Iichenijormis for 24 hours (37°C, 90 rpm).These cultures 
were used to prepare nutrient agar seeded plates ( 15 ml of nutrient agar per plate) . To 
examine cross-resistance, Oxoid multodisks ( Code 30-44K) containing 8 antibiotics 
disks were used . Multodisks were placed on the surface of seeded plates, and these 
were incubated overnight at 370C , and zones of inhibition were observed . 
Cross-resistance of pyrithione-treated cells of Kl.pneumoniae to chloramphenicol and 
8-hydroxyquinoline was also examined in CDM . The MICs of chloramphenicol, 
8-hydroxyquinoline and pyrithione against the control and pyrithione-treated cultures of 
KI. pneumoniae were determined in CDM as described above in section 2.2.4 .. 
2.2.14.4. Fatty acid profiles of control and pyrithione-treated cells of KI pneumoniae 
2.2.14.4.1. Preparation of fatty acid methyl esters 
Batch cultures (2xl00 ml CDM) of KI. pneumoniae were prepared containing 0.0 
and 5.0 Jlg/ml pyrithione, and incubated for 24 hours (37°C, 90 rpm). Cells were 
harvested by centrifugation at 4000 rpm for 15 minutes, washed three times with 
sterile distilled water and frozen at -70°C. Cells were then freeze-dried in a Taddington 
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freeze-drier . To esterify and extract fatty aCids from the freeze-dried cells, a method 
based on that outlined by Stretton and Dart (1976) was used . Freeze-dried cells were 
placed in a quick-fit (100ml) round flask containing 15 m1 of re-distilled methanol with 
1-2 drops of concentrated sulphuric acid , and incubated at 37°C for 48 hours . 
Mixtures were filtered through 0.451lm Whatman GF/F glass fibre filters, and the 
filtrates were extracted twice with equal volumes of re-distilled hexane . The hexane 
extract was then reduced in volume to about 0.5-1.0 m1 under vacuum using a rotary 
evaporator. This was then ready for analysis by gas-liquid chromatography (GLC, see 
below). 
2.2.14.4.2. GLC of fatty acids methyl esters ( FAME ) 
(a) Column: 
A 1.5m x 4mm glass column was packed under vacuum with 10% 
diethylglycolsuccinate (DEGS) on 100/120 mesh Chromosorb W . The column was 
then conditioned by placing it in a nitrogen flow near its maximum operating 
temperature (170°C) for a day without being connected to the detector . 
(b) Chromatograph: 
Pye Series 104. 
(c) Detector: 
Flame ionisation detector. 
(d) Syringes: 
SGE syringes of 1.0J.l.l and 5.01ll capacities were used . 
(e) Conditions: 
Nitrogen flow (40 m1 / minute) , temperature (1700C) . 
(f) Standards: 
Methyl esters of the following fatty acids were purchased from Sigrna : capric acid 
(ClO:0) , lauric acid (C12:0) ,myristic acid (C14:0) , palmitic acid (C 1 6:0) , stearic 
acid (C18:0) and arachidic acid (C20:0) methyl esters. 
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2.2.15. The influence of pyrithione on the morphology of micro-organisms 
Kl. pneumoniae , B. licheniformis NCm 6346 and C. albicans NCYC 597 were 
used in this study. Cells were grown in 100 ml batches of CDM containing various 
concentrations of pyrithione . To prepare samples for analysis by scanning electron 
microscopy , the method of Ghannoum and Al-khars (1984) was used. Glutaraldehyde 
was added to cultures to give a fmal concentration of 1.5% (wlv) . After 2 minutes 
contact, the cells were removed by centrifugation at 4000 rpm (4°C, 15 minutes) and 
resuspended in 2 ml of 5% (wlv) glutaraldehyde solution at 4°C for 16 hours. Cells 
were then collected by centrifugation, washed three times with distilled water and 
resuspended in distilled water to give the required density (faint opalescence) .One 
drop ( approximately 301Jl) from each suspension was allowed to air-dry on clean 
circular glass cover slip and then dehydrated over CaCl2 (anhydrous) under partial 
vacuum. Samples were then coated with gold-palladium in a high vacuum coating 
unit, until a coating of approximately IOnm thickness was achieved. Samples were 
then examined in an ISI-SS40 scanning electron microscope at an accelerating voltage 
of lOkV. 
53 
CHAPTER THREE 
RESULTS 
3.1. MIC Detenninations of pyrithione and related compounds ( tube dilution) 
Pyrithione inhibited the growth of all 15 species (20 strains) examined. In nutrient 
broth , MlCs ranged from 0.03 to 80Jlg/mI ; S. cerevisiae was the most sensitive 
(0.03Jlg/mI) whilst Ps. aeruginosa showed the highest resistance amongst the 
organisms tested (80Jlg/mI ; Table 3.1) . In addition, it was observed that KI. 
pneumoniae , Salm. abony , S. marcescens and P. vulgaris always showed 
turbidity in some tubes containing the higher concentrations of the drug well above the 
MIC range. Microscopic examination and viability testing of loopful samples onto 
nutrient agar, showed growth in these tubes. 
Table 3.2 shows the MlCs of pyrithione determined in CDM against five selected 
organisms. Ps. aeruginosa , B. lichenifonnis and C. albicans were more sensitive in 
CDM than in nutrient broth , although Ps. aeruginosa remained relatively resistant. 
E. coli and KI. pneumoniae did not show considerable variations in their sensitivity 
compared with that obtained in nutrient broth . 
Table 3.3 shows the MIC values of pyrithione-related compounds against 
KI. pneumoniae, B. licheniformis and C. albicans. None of the four compounds: 
2-mercaptopyridine (MP) , 2-mercaptopyrimidine (MPY) , 2-mercaptonicotinic acid 
(MNA) and 3-hydroxy-2-mercaptopyridine (HMP) showed any apparent antimicrobial 
activity against KI. pneumoniae at concentrations up to l00Jlg/mI . All four 
compounds inhibited the growth of B. licheniformis with MIC values of O.625Jlg/mI 
(HMP) , 2.5Jlg/mI (MPY) , 5.0Jlg/mI (MP) and 50Jlg/mI (MNA) . MNA was inactive 
against C.albicans ( MIC > l00Jlg/mI ) , whilst MP , MPY and HMP were equally 
active against C. albicans with MIC value of 12.5Jlg/mI each . 
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Table 3.1 : Minimum inhibitory concentrations ( MIC ) of pyrithione against micro-
organisms in nutrient broth . 
Micro-organism MIC (J.1gfml) 
Gram-negative bacteria 
Escherichia coli NCTC 9001 2.5 
Klebsiella pnewnoniae NCm 8267 2.5 
Proteus vulgaris NCm 8067 5.0 
Pseudomonas aeruginosa NCTC 6749 80.0 
Salmonella abony NCTC 6017 2.5 
Serratia marcescens NCTC 1377 10.0 
Gram-positive bacteria 
Bacillus cereus LUT 11755 0.6 
B.licheniformis Ncm 6346 0.6 
B.licheniformis NCTC 1097 0.6 
B. megaterium NCm 8291 0.6 
B. subtilis NCm 3610 0.3 
Mycobaterium phlei NCTC 8151 2.5 
Staphylococcus aureus NCm 8625 0.6 
Yeasts 
Candida albicans NCYC 597 0.15 
C. albicans NCYC 1363 1.25 
C. albicans NCYC 1466 0.15 
C. albicans A39 0.3 
Debaryomyces hansenii NCYC 8 0.2 
Saccharomyces cerevisiae NCYC 345 0.03 
S. cerevisiae NCYC 975 0.03 
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Table 3.2 : Minimum inhibitory concentrations ( MIC) of pyrithione against micro-
organisms in chemically defmed medium . 
Micro-organism 
Pseudomonas aeruginosa NCTC 6749 
Escherichia coli NCTC 9001 
Klebsiella pneumoniae NCm 8267 
Bacillus lichenifomUs NCm 6346 
Candida albicans NCYC 597 
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MIC (11g/rnl) 
20.0 
2.5 
5.0 
0.05 
0.05 
Table 3.3 : Minimum inhibitory concentrations ( MIC ) of pyrithione-related 
compounds against micro-organisms in chemically defined medium . 
Micro-organism 
MP* 
Klebsiella pnewnoniae >100 
NCm 8267 
Bacillus lichenifonnis 5.0 
NCm 6346 
Candida albicans 12.5 
NCYC597 
MIC (jJ.g/ml) 
MPY* 
>100 
2.5 
12.5 
MNA* 
>100 
50 
>100 
* : MP, 2-mercaptopyridine ; MPY , 2-mercaptopyrimidine ; 
HMP* 
>100 
0.625 
12.5 
MNA , 2-mercaptonicotinic acid; HMP , 3-hydroxy-2-mercaptopyridine 
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3.2. Effect of pyrithione on the growth of micro-organisms 
Figures 3.1 ,3.2 and 3.3 show the effect of pyrithione on the growth of 
Kl. pneumoniae , B. licheniformis and C. albicans, respectively. Both bacteria 
showed an overall similarity of growth curves in the presence of increasing sub-
inhibitory concentrations of pyrithione , with an extended Jag phase, the length of 
which depended on the concentration of the drug ( Figs 3.1 and 3.2 ) . After this Jag 
phase, both organisms grew at a rate similar to that of the control ( untreated) culture . 
For KI. pneumoniae , 5 and 61lg/ml pyrithione induced lags of greater than 600 
minutes after which recovery was occasionally observed. C. albicans, however, 
showed a different response to pyrithione . The drug reduced the overall growth rate of 
the organism, the effect on growth increasing with drug concentration and did not 
induce an obvious lag phase. At high concentrations, pyrithione inhibited the growth 
of all three organisms . 
The effect of the re-addition ( re-challenge) of pyrithione on cultures of 
Kl. pneumoniae and B. licheniformis initially grown in the presence of pyrithione is 
illustrated in Figs 3.4 and 3.5 . Cultures showed the established ( Figs 3.1 and 3.2 ) 
pattern of an extended lag phase in the presence of initial levels of pyrithione . Once 
growth was established, however, further additions of pyrithione had little or no effect 
on overall growth rate, which in each case was similar to that of the control (untreated) 
culture. For C. albicans (Fig 3.6 ) , growth rate after re-addition of pyrithione was 
slightly reduced . 
Figs 3.7 and 3.8 show the effect of adding concentrations of pyrithione to mid-log 
phase ( 0.0. 0.4 ) culrures of Kl. pneumoniae and B. licheniformis , respectively. A 
drug concentration-dependent Jag phase was observed but the length of the lag phase 
was reduced compared with that observed with the same concentration of pyrithione 
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present from the commencement of incubation (Figs 3.1 and 3.2 ) . Adding pyrithione 
to mid-exponential phase cultures of C. albicans (Fig 3.9 ) reduced gtowth rate in a 
drug concentration-dependent manner as before ( Fig 3.3 ) . 
3.3 Effect of pyrithione on the viability of Kl Dneumoniae and C. albicans 
The effects of pyrithione on the optical density and viability of growing cultures of 
Kl. pneunwniae are shown in Figure 3.10 . The sets of curves for optical density (Fig 
3. lOa ) and viability ( Fig 3. lOb ) are essentially similar. Both show, in the presence 
of pyrithione , a first stage ( lag ) during which optical density ( Fig 3.lOa ) and viable 
count (Fig 3. !Ob ) remain virtually constant for a time dependent on pyrithione 
concentration. This is followed by a phase during which both optical density and 
viability increase at a rate similar to that of untreated controls . In the case of 
C. albicans, the drug concentration-dependent reduction in growth rate as monitored 
by optical density ( Fig 3.11a ) is also mirror-imaged with viability curves 
(Fig 3.11b ) . 
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Figure 3.1 : The effect of various concentrations of pyrithione on the 
growth ( CDM • 37°C. 90rpm ) of Klebsiella pneumoniae; 
• : O.O~g!ml 
o : l.O~g!ml 
• : 2.0~g!ml 
o : 3.0~g!ml 
b. : 4.0~g!ml 
+ : 5.0~g!ml 
X: 6.0~g!ml 
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Figure 3.2 : The effect of various concentrations of pyrithione on the 
growth (CDM ,37°C, 90 rpm) of B. licheniformis ; 
• : O.Ojlg/ml 
o : O.OO2jlg/ml 
• : O.OO4jlg/ml 
o : O.OO6jlg/ml 
.6. : O.OO8jlg/ml 
+ : O.Oljlg/ml 
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Figure 3.3 : The effect of various concentrations of pyrithione on the 
growth ( CDM ,37°C, 90 rpm ) of Candida albicans ; 
• : O.OIlg/ml 
o : O.OO21lg/ml 
• : O·OO4Ilg/ml 
o : O.OO61lg/ml 
c" : O.OO81lg/ml 
+ : O.Olllg/ml 
X : O.021lg/ml 
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Figure 3.4 : The effect of re-challenge* ( arrows) with pyrithione on the 
growth ( CDM ,37°C, 90 rpm ) of Klebsiella pneumoniae ; 
• : O.OjJ.g/ml ( final conc. O.OIlg/ml ) 
o : 1.01lg/ml ( final conc. 2.01lg/ml ) 
• : 2.0jJ.g/ml ( final conc. 4.01lg/ml ) 
o : 3.0jJ.g/ml ( final conc. 6.01lg/ml ) 
· ~ : 4.0jJ.g/ml ( final conc. 8.01lg/ml ) 
+ : 5.0 Ilg/ml ( final conc. 1O.01lg/ml) 
* concentration after re-challenge was in each case at least that initialy 
present. 
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Figure 3.5 : The effect of re-challenge* ( arrows) with pyrithione on the 
growth ( CDM , 370 , 90 rpm ) of Bacillus licheniformis ; 
• : O.O!Lg/ml (final conc. O.O!Lg/ml ) 
o : 0.OO211g/ml ( final conc. 0.00411g/m1 ) 
• : O.OO4I1g/ml ( final conc. 0.OO811g/m1 ) 
o : 0.OO611g/ml ( final conc. 0.01211g/m1) 
t::. : 0.OO811g/ml ( final conc. 0.0 l611g/m1 ) 
+ : O.Oll1g/ml ( final conc. 0.0211g/rnl ) 
X : 0.0511g/ml (final conc. O.ll1g/rnl ) 
o : O.ll1g/ml ( final conc. 0.211g/ml ) 
* concentration after re-challenge was in each case at least that initially 
present . 
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Figure 3.6 : The effect of re-challenge* ( arrows) with pyrithione on the 
growth ( CDM • 37°C. 90 rpm ) of Candida albicans ; 
• : O.O~g/ml ( final conc. O.O~g/ml ) 
o : O.OO2~g/ml ( final conc. O.OO4~g/m1 ) 
• : O.OO4~g/ml ( final conc. O.OO8~g/m1 ) 
o : O.OO6~g/ml ( final conc. O.012~g/m1 ) 
~ : O.OO8~g/ml (final conc. O.OI6~g/m1) 
+ : O.01~g/ml ( final conc. O.Q2~g/ml ) 
X : O.05~g/ml ( final conc. O.l~g/ml ) 
<> : O.l~g/ml ( final conc. O.2~g/ml ) 
* concentration after re-challenge was in each case at least that initially 
present. 
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Figure 3.7 : The effect of adding ( arrows) pyrithione to exponentially 
growing ( CDM • 37°C. 90 rpm ) cells of Klebsiella 
pneumoniae ; final pyrithione concentrations: 
• : O.OIlg/ml 
o : l.OIlg/ml 
• : 2.01lg/ml 
o : 3.01lg/ml 
tJ. : 4.01lg/ml 
+ : 5.01lg/ml 
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Figure 3.8 : The effect of adding ( arrows) pyrithione to exponentially 
growing ( CDM • 37°C. 90 rpm ) cells of Bacillus 
Iicheniformis ; final pyrithione concentrations: 
• :O.O~g/ml 
o : O.OO2~g/ml 
• : O.OO4~g/ml 
o : O.OO6~g/ml 
~ : O.OO8~g/ml 
+ : O.Ol~g/ml 
X : O.05~g/ml 
<> : O.l~g/ml 
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Figme 3.9 : The effect of adding ( arrows) pyrithione to exponentially 
growing ( CDM ,37°C, 90 rpm ) cells of Candida albicans ; 
final pyrithione concentrations: 
• : O.OI1g1ml 
o : O.OO211g1ml 
• : O·OO4I1g1ml 
o : O.OO611g1ml 
I::; : O.OO811g1ml 
+ : O.Oll1g1ml 
X : O.0511g1ml 
o : O.ll1g1ml 
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Figure 3.10 : The effect of pyrithione on the growth and viability of 
KZ. pneunwniae ( CDM • 37°C. 90 rpm ) ; pyrithione 
concentrations : 
• 
0 
• 
0 
b. 
(a) optical density 
(b) viable count 
: O.OI1g/ml 
: 1.011g/ml 
: 2.011g/ml 
: 4.011g/ml 
: 5.011g/ml 
10 
.---,. 
E 
c: 
0 
Lt') 
~ 
>-~ 
Vl 1 
Z 
w 
Cl 
....J 
<I: 
U 
~ 
a.. 
0 
0.1+---~----'-----r----'------r------' 
o 100 200 300 400 500 600 
TIME (MINUTES) 
69a 
100 
10 
~ 
.. 
0 
-X 
::::> 
..... () 
1 
O.l-1---__r--___,---~--__r--___,--___, 
o 100 200 300 400 500 600 
TIME (MINUTES) 
6gb 
Figure 3.11 : The effect of various concentrations of pyrithione on the 
growth and viability of C. albicans ( CDM ,37°C, 90 rpm ) ; 
• : O.OI1g/ml 
o : 0.OO211g/ml 
• : O·OO4I1g/ml 
o : O·OO6I1g/ml 
~ : 0.OO811g/ml 
+ : O.OII1g/ml 
X : 0.0511g/ml 
(a) optical density 
(b) viable count 
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3.4. Cell size distribution of division-inhibited ( ampicillin) cells of KI pnewnoniae in 
the presence of pyrithione 
The MIC of ampicillin against B. licheniformis in CDM is 1.61lg/ml, whereas the 
growth of Kl. pneumoniae was not inhibited at l00llglml or less (Table 3.4 ) . 
Preliminary experiments showed that in CDM ( 37°C, 90 rpm) containing 50llglml 
ampicillin, cells of Kl. pneumoniae grew ( increased in mass I optical density ) 
without division, at an uninhibited rate ( equivalent to control rate ) . This was 
confirmed by both microscopy ( in which fllamentous growth was observed ), cell 
count and assessment of cell size distribution at variuos times. 
---
The analysis of the cell size distribution of cultures of Kl. pneumoniae incubated 
in CDM and in CDM containing 21lglml pyrithione or 50llglml ampicillin is shown in 
Figs 3.12 and 3.13 ,respectively . Control ( untreated) cultures have unirnodal cells 
size ( equivalent spheres) profIles with a mean size of 1.23Jlm3 that are essentially 
unchanged following incubation ( Fig 3.12 ) . Cultures incubated in the presence of 
50llglml ampicillin show unimodal profIles of increased mean size ( 1.96~ ) after 
120 minutes ( Fig 3.13 ) . Cultures incubated in the presence of both ampicillin 
( 50llglml ) and pyrithione ( 2.OJ.1g1ml ) for up to 120 minutes had size profiles that 
were unimodal and similar to that of the drug-free control ( cf. Figs 3.12 and 3.14 ) . 
Cultures incubated further ( 240 - 360 minutes; fig 3.14 ) demonstrated bimodal size 
distributions following the appearance of a population of increased mean size. 
Prolonged incubation ( 480 minutes) produced cultures with a shift to a unirnodal 
population of increased mean size ( 2.47~) with concurrent loss of the population of 
smaller mean size ( 1.23Jlm3 ; Fig 3.14 ) . 
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Table 3.4 : Minimum inhibitory concentrations ( MIC ; tube dilution) of ampicillin 
against miCT(K)fganisms in chemically defined medium. 
Micro-organism 
Kt. pnewnoniae NCm 8267 
B.licheniformis NCm 6346 
72 
MIC (l1g/ml) 
>100 
1.6 
Figure 3.12 : Cell size( equivalent spheres) distribution of 
Kl. pneumoniae grown in CDM ( 37°C. 90 rpm ) after: 
• : 0.0 minutes 
o : 120 minutes 
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Figure 3.13 : Cell size( equivalent spheres) distribution of 
Kl. pneumoniae grown in CDM ( 37°C. 90 rpm ) after: 
• : 0.0 minutes ( 50Ilg/ml ampicillin or 2.01lg/rnl 
pyrithione) 
o : 120 minutes ( 2.0jJ.g/ml pyrithione ) 
• : 120 minutes ( 50jJ.g/ml ampicillin ) 
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Figure 3.14 : Cell size ( equivalent spheres) disnibution of 
Kt. pneumoniae grown in CDM ( 37°C, 90 rpm ) containing 
50Jlglml ampicillin and 2.0Jlglml pyrithione , after: 
• : 0.0 minutes 
0 : 120 minutes 
• : 240 minutes 
0 : 360 minutes 
C, : 480 minutes 
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3.5. Interaction of l!yrithione with EDTA 
3.5.1. Agar diffusion 
EDTA interacted antagonistically with pyrithione against Kl. pneumoniae , 
B. licheniformis and C. albicans (Fig 3.15 a , b and c , respectively) . The 
antagonism was characterised by reduction of pyrithione's inhibition wne size around 
the area where the two paper strips overlap. The antagonism was most evident with 
B.licheniformis (Fig 3.l5b) followed by C.albicans (Fig 3.l5c) and 
Kl. pneumoniae ( Fig 3.l5a) . 
3.5.2. Influence of EDTA on l!yri1hione-induced changeS in growth rate 
Table 3.5 shows the MIC values of EDTA against Kl. pneumoniae , 
B.licheniformis and C. albicans. The concentration ofEDTA up to 200Ilg/ml did not 
inhibit the growth of either Kl. pneumoniae or B. licheniformis . The MIC of EDTA 
against C. albicans was 501lg/ml. 
In the case of Kl. pneumoniae (Fig 3.16) ,EDTA (50Ilg/ml) showed some 
antagonism shone,! ling the observed lag phase induced by pyrithione ( 3.01lg/ml ) . 
EDTA ( 501lg/ml ) completely antagonised the action of pyrithione ( O.OO2Ilg/ml ) 
against B. licheniformis (Fig 3.17 ) . This supports the strong antagonism observed 
on solid medium previously described (Fig 3.l5b). With C. albicans (Fig 3.18), 
EDTA ( 101lg/ml ) reduced the effectiveness of pyrithione ( O.OlJlg/mi ) though the 
new growth rate was less than that of the control ( untreated) culture . 
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Figure 3.15: Interaction between pyrithione andEDTA (COMA, 37°C); 
(a) Klebsiella pneunwniae ; pyrithione 0.1 % , snip P ; 
EDT A 1.0% , snip E . 
(b) Bacillus licheniformis ; pyrithione 0.01 % , snip P ; 
EDT A 1.0% , strip E . 
(c) Candida albicans; pyrithione 0.01%, snip P; 
EDT A 1.0% , snip E. 
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Table 3.5 : Minimum inhibitory concentrations of EDT A against micnrorganisms 
in chemically defined medium. 
Micro-organism 
Klebsiellil pneumoniae NCm 8267 
Bacillus licheniformis NCm 6346 
Candida albicans NCYC 5fJ7 
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MIC ()lg/ml) 
>200 
>200 
50.0 
Figure 3.16: Influence ofEDTA on the growth (CDM, 37°C, 9Orpm) of 
pyrithione-treated cells of Klebsiella pneumoniae ; 
• : connol ( untreated ) 
o : 3.0 J.1g/ml pyrithione 
• : 50J.1g/ml EDT A 
o : 3.0J.1g/ml pyrithione plus 50J.1g/ml EDT A 
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400 500 
Figure 3.17 : Influence of EDT A on the growth ( CDM ,37°C, 90 rpm ) 
of pyrithione-treated cells of Bacillus licheniformis ; 
• : control ( untreated ) 
• : O.OO~g/ml pyrithione 
o : 50IlWml EDTA 
o : O.OO21lg/ml pyrithione plus 501lg/ml EDTA 
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Figure 3.18: Influence ofEDTA on the growth (CDM ,37°C, 90 rpm) 
of pyrithione-treated cells of Candida albicans ; 
• : control ( untreated ) 
o : O.01Ilg!ml pyrithione 
• : 10Ilglml EDTA 
o : O.Olllglml pyrithione plus 10IlglmlEDTA 
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3.6. Interaction of metal ions with pyrithione 
3.6.1. In nutrient agar 
Figures 3.19 , 3.20 and 3.21 show the interaction of pyrithione with some metal 
ions in nutrient agar against KI. pneumoniae , B. lichenifonnis and C. albicans , 
respectively. Synergy was observed between pyrihione dnd Zn2+ against 
~ 
KI. pneumoniae (Fig 3.19a) , but no significant interaction was observed between 
pyrithione and any of the other metal ions: Mg2+ , Mn2+, ea2+ and Fe3+ (Fig 3.19 b, 
c , d and e , respectiveJ y ) . 
Against B. lichenifonnis ( Fig 3.20 ) , slight synergy was observed between 
pyrithione and either Mg2+ (Fig 3.20b ) , or ea2+ ( Fig 3.2Od ) or Fe3+ ( Fig 3.2Oe ) , 
but no apparent interaction between pyrithione and either Zn2+ ( Fig 3.20a) or Mn2+ 
( Fig 3.2Oc ) was observed. Synergy was apparent between pyrithione and all the five 
metal ions against C. albicans ( Fig 3.21 ) . 
3.6.2. In CDMA 
Figures 3.22 , 3.23 and 3.24 show the interaction between pyrithione and metal 
ions in CDMA against KI. pneumoniae , B .lichenifonnis and C. albicans , 
respectively. In the case of KI. pneumoniae, slight synergy was observed between 
pyrithione and either Zn2+ ( Fig 3.22a ) or Fe3+ ( Fig 3.22e ) , but no significant 
interaction was observed between pyrithione and either Mg2+ , Mn2+ or Ca2+ ( Fig 3.22 
b , c and d , respectively) . 
AgainstB.lichenifonnis (Fig 3.23), the action ofpyrithione was slightly 
potentiated by Zn2+ ( Fig 3.23a ) , Mn2+ ( Fig 3.23c ) and Fe3+ ( Fig 3.23e ) . No 
interaction was observed between pyrithione and either Mg2+ ( Fig 3.23b ) or ea2+ 
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( Fig 3.23d ) . 
In the case of C. albicans (Fig 3.24 ) , the action of pyrithione was slightly 
potentiated by Zn2+ ( Fig 3.24a ) but not by any of the other ions: Mg2+ ( Fig 3.24b ) , 
Mn2+ ( Fig 3.24c ) , Ca2+ ( Fig 3.24d ) and Fe3+ ( Fig 3.24e ) . 
3.7. Interaction berween pyrithione and 8-hydroxyquinoline against micro-organisms 
No apparent interaction was observed berween pyrithione and 8-hydroxyquinoline 
in either nutrient agar ( Fig 3.25 ) or COMA (Fig 3.26 ) against Kl. pneumoniae , 
B. licheniformis or C. albicans . 
3.8. The antimicrobial action of 8-hydroxyquinoline 
3.8.1. MIC determinations 
Table ( 3.6 ) shows the MIC values for 8-hydroxyquinoline in COM against 
Kl. pneumoniae , B. licheniformis and C. albicans. Kl. pneumoniae was the most 
resistant ( MIC 50Ilg/ml ) whereas C. albicans was the most sensitive 
(MIC O.151lg/ml). B.licheniformis was also more sensitive than Kl. pneumoniae 
with an MIC value of O.6251lg/ml . 
3.8.2. Effect on growth 
Figure 3.27 shows the effect of 8-hydroxyquinoline on the viability of 
Kl. pneumoniae . An initial phase of highly reduced growth rate (Jag phase, the 
length of which depended on the concentration of the drug ) was observed. This was 
followed, in the presence of sub-inhibitory concentrations of 8-hydroxyquinoline , by 
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an increase in viability at a rate approaching that of the control ( untreated) culture ( Fig 
3.27) . In the case of B. licheniformis ( Fig 3.28 ) and C. albicans (Fig 3.29) • 
optical density measurements were used to monitor growth. In the presence of sub-
inhibitory concentrations of 8-hydroxyquinoline • B. lichenifonnis showed an initial 
lag phase. the length of which depended on the drug concentration. This was followed 
by growth at a rate similar to that of the control ( untreated) culture ( Fig 3.28 ) . The 
effect of 8-hydroxyquinoline on the growth of C. albicans was characterised by drug 
concentration dependent reduction of the overall growth rate of the organism. but no 
obvious lag phase was induced ( Fig 3.29 ) . 
Table 3.6 : Minimum inhibitory concentrations ( MIC ) of 8-hydroxyquinoline 
against micro-organisms in chemically defined medium. 
Micro-organism 
Klebsiella pneumoniae NCm 8267 
Bacillw; licheniformis NCm 6346 
Candida albicans NCYC 579 
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MIC(~g/ml) 
50.0 
0.625 
0.15 
---------------------._---
Figure 3.19 : Interaction between pyrithione and metal ions against 
Kl. pneumoniae ( Nutrient Agar, 37°C) ; 
(a) Pyrithione 0.1 % , strip P ; ZnCl2 0.01 % , strip Zn . 
(b) Pyrithione 0.1 % , strip P ; MgS04.7H20 0.01 % , strip Mg . 
(c) Pyrithione 0.1 % , strip P ; MnClN H20 0.01 % , strip Mn . 
(d) Pyrithione 0.1%, strip P; CaCl2 0.01%, strip Ca. 
(e) Pyrithione 0.1% ,strip P; FeCl3 0.01%, strip Fe. 
a 
c 
d e 
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Figure 3.20 : Interaction between pyrithione and metal ions against 
B. licheniformis ( Nutrient Agar, 37°C) ; 
(a) Pyrithione 0.01 % , strip P ; ZnCI2 0.01 % , strip Zn . 
(b) Pyrithione 0.01 % , strip P ; MgS04.7H20 0.01 % , strip Mg . 
(c) Pyrithione 0.01 % , strip P ; MnCl2-4H20 0.01 % , strip Mn . 
(d) Pyrithione 0.01 % , strip P ; CaC12 0.01 % , strip Ca . 
(e) Pyrithione 0.01 % , strip P ; FeCI3 om % , strip Fe. 
a b 
c 
d e 
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Figure 3.21 : Interaction between pyrithione and metal ions against 
C. albicans C Nutrient Agar, 37°C) ; 
Ca) Pyrithione 0.01 % , strip P ; ZnC12 0.01 % , strip Zn . 
(b) Pyrithione 0.01 % , strip P; MgS04.7H20 0.01 % ,strip Mg . 
Cc) Pyrithione 0.01 % , strip P ; MnCl2-4R20 0.01 % , strip Mn . 
Cd) Pyrithione 0.01 % , strip P ; CaC12 0.01 % , strip Ca . 
Ce) Pyrithione 0.01 % , strip P ; FeC13 0.01 % , strip Fe . 
a b 
c 
d e 
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Figure 3.22 : Interaction between pyrithione and metal ions against 
KZ. pnewnoniae ( COMA • 37°C) ; 
(a) Pyrithione 0.1 % • strip P ; ZnC12 0.Q1 % • strip Zn . 
(b) Pyrithione 0.1% • strip P; MgS04.7H20 0.01% • strip Mg . 
(c) Pyrithione 0.1 % • strip P; MnCIN H20 0.01 % • strip Mn . 
(d) Pyrithione 0.1 % • strip P ; CaCl2 0.01 % • strip Ca . 
(e) Pyrithione 0.1 % • strip P ; FeCl3 0.01 % • strip Fe . 
a b 
c 
d e 
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Figure 3.23 : Interaction between pyrithione and metal ions against 
B.licheniformis (CDMA. 37°C); 
(a) Pyrithione 0.001 % • snip P ; ZnCI2 om % • snip Zn . 
(b) Pyrithione 0.001% • snip P; MgS04.7Hp 0.01 % • snip Mg . 
(c) Pyrithione 0.001 % • snip P ; MnClN H20 0.01 % • snip Mn . 
(d) Pyrithione 0.001 % • snip P ; CaCI2 0.01 % • snip Ca . 
(e) Pyrithione 0.001 % • snip P ; FeCI3 0.01 % • snip Fe . 
a b 
d e 
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Figure 3.24 : Interaction between pyrithione and metal ions against 
C. albicans C COMA, 37°C); 
Ca) Pyrithione 0.001 % , strip P ; ZnCl2 om % • strip Zn . 
Cb) Pyrithione 0.001% , strip P; MgS04.7H20 0.01 % , strip Mg. 
Cc) Pyrithione 0.001 % , strip P ; MnCI2-4H20 0.01 % , strip Mn . 
Cd) Pyrithione 0.001 % , strip P ; CaCl2 om % • strip Ca . 
Ce) Pyrithione 0.001 % , strip P ; FeCl3 0.01 % • strip Fe . 
a b 
d e 
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Figure 3.25 : Interaction between pyrithione and 8-hydroxyquinoline 
( Nutrient Agar, 37°C) against: 
(a) Klebsiella pnewnoniae ; pyrithione 0.1 % , strip P ; 
8-hydroxyquinoline 0.1 % , strip HQ . 
(b) Bacillus licheniformis ; pyrithione 0.01% , strip P ; 
8-hydroxyquinoline 0.1 % , strip HQ . 
(c) Candida albicans; pyrithione 0.01 % ,strip P ; 
8-hydroxyquinoline 0.1 % , strip HQ . 
a 
b 
c 
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Figure 3.26 : Interaction between pyrithione and 8-hydroxyquinoline 
( CDMA ,37°C) against: 
(a) Klebsiella pneumoniae ; pyrithione 0.1 % , strip P ; 
8-hydroxyquinoline 0.1 % , strip HQ . 
(b) Bacillus lichenifonnis ; pyrithione 0.001 % , strip P ; 
8-hydroxyquino1ine 0.01 % , strip HQ . 
(c) Candida albicans; pyrithione 0.001 % , snip P; 
8-hydroxyquino1ine 0.01 % , strip HQ . 
a 
t 
c 
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Figure 3.27 : The effect of various concentrations of 8-hydroxyquinoline on 
the viability ( CDM ,37°C, 90 rpm) of Klebsiella 
pneumoniae ; 
• : O.OIlg/ml 
o : IDl1g/ml 
• : 2DI1g/ml 
o : 3D11g/ml 
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Figure 3.28 : The effect of various concentrations of 8-hydroxyquinoline on 
the growth (CDM ,37°C, 90 rpm) of Bacillus 
lichenifomUs ; 
• :O.O~g/ml 
o : O.025~g/ml 
• : O.05~g/ml 
o : O.075~g/ml 
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Figure 3.29 : The effect of various concentrations of 8-hydroxyquinoline on 
the growth ( CDM ,37°C, 90 rpm ) of Candida albicans ; 
• : O.OJlg/ml 
o : O.025Jlg/ml 
• : O.05Jlg/ml 
o : O.075Jlg/ml 
/); : O.lJlg/ml 
+ : O.2Jlg/ml 
X : O.3Jlg/ml 
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3.9. Effect of pyrithione on the incO!;poration of radiolabelled substrates by 
KI pnewnoniae and B. licbeniforrois 
3.9.1. K1. Pneumonjae 
The incorporation of 14C-glycine by KI. pnewnoniae was rapidly inhibited by 
pyrithione at 1.0, 2.5 and 5.01lg/ml ( Fig 3.30 ) . Glycine incorporation ceased within 
2 minutes of the addition of pyrithione . However, prolonged incubation of the cells 
( 420 minutes, allowing re-establishment of growth approximately 120 minutes after 
the addition of pyrithione ) in the presence of pyrithione ( 2.51lg/ml ) showed that 
glycine incorporation continued at a reduced rate compared with control ( untreated ) 
cells ( Fig 3.31 ) . 
The incorporation of 14C-thymidine was also inhibited by pyrithione within 2 
minutes of the addition of the drug ( Fig 3.32 ) , and did not recommence in the 
presence of 2.5 Ilg/ml of the drug during prolonged ( 420 minutes) incubation 
(Fig 3.33 ) . 
The incorporation of 14C-uridine was also inhibited within 2 minutes of the 
addition of pyrithione ( Fig 3.34 ) . However, 14C-uridine incorporation recommenced 
in the presence of 2.51lg/ml of pyrithione at a rate similar to that of the control during 
prolonged incubation ( 300 minutes) which allowed, as before, recommencement of 
the growth approximately 120 minutes after the addition of the drug ( Fig 3.35 ) . 
3.9.2. B lichenj.formjs 
The incorporation of 14C-glycine ( Fig 3.36 ) , 14C-thymidine ( Fig 3.37 ) and 
14C-uridine ( Fig 3.38 ) was completely inhibited within 3-5 minutes of the addition of 
pyrithione at om ,0.025 and 0.051lg/mi . 
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Figure 3.30 : The effect of pyrithione ( arrow ) at various concentrations on 
the inoorporation of 14C-gJycine ( 0.2~Ci ) by Klebsiella 
pneUlTUJniae ( CDM ,37°C, 90 rpm ) ; 
• : O.OI1g/ml 
o : 1.011g/ml 
• : 2.511g/ml 
o : 5.011g/ml 
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Figme 3.31 : The effect of pyrithione concentration ( arrow ) on 
the incorporation of14C-gIycine ( O.2I!Ci ) by Klebsiella 
pneumoniae ( CDM • 37°C. 90 rpm ) • dming prolonged 
incubation; 
• : O.Ol!glml 
o : 2.5l!glml 
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Figure 3.32 : The effect of pyrithione ( arrow ) at various concentrations on 
the incorporation of 14C-thymidine ( O.2~Ci ) by Klebsiella 
pneumoniae ( CDM ,37°C, 90 rpm ) ; 
• : O.OI1g/ml 
o : l.OI1g/ml 
• : 2.5I1g/ml 
o : 5.011g/ml 
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Figure 3.33 : The effect of pyrithione concentration ( arrow ) on the 
incorporation of l 4C-thymidine ( O.2~Ci ) by Klebsiella 
pneumoniae ( CDM ,37°C, 90 rpm) ,during prolonged 
incubation; 
• : O.Ojlglml 
o : 2.5jlglml 
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Figure 3.34 : The effect of pyrithione ( arrow ) at various concentrations on 
the incorporation of l"C-uridine ( 0.211Ci ) by Klebsiella 
pneumoniae ( CDM ,37°C, 90 rpm ) ; 
• : O.OI1g/ml 
o : 1.011g/ml 
• : 2.511g/ml 
o : 5.011g/ml 
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Figure 3.35 : The effect of pyrithione concentration ( mow ) on the 
incorporation of 14C-uridine ( 0.21lCi ) by Klebsiella 
pneumoniae ( CDM ,37°C, 90 rpm ) ,during prolonged 
incubation ; 
• : O.Ollglml 
o : 2.51lglml 
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Figure 3.36 : The effect of pyrithione ( arrow ) at various concentrations on 
the incorporation of 14C-gJycine ( O.2JlCi ) by Bacillus 
licheniformis ( CDM • 37°C. 90 rpm ) ; 
• : O.OJlglml 
o : O.OJllglml 
• : O.0251lglml 
o : O.051lglml 
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Figure 3.37 : The effect of pyrithione ( arrow ) at various concentrations on 
the incorporation of 14C-thymidine ( O.2~Ci ) by Bacillus 
licheniformis ( CDM ,37°C, 90 rpm ) ; 
• :O.O~g/ml 
o : O.OII1g/ml 
• : O.025~g/ml 
o : O.0511g/ml 
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Figure 3.38 : The effect of pyrithione ( arrow ) at various concentrations on 
the incorporation of 14C-uridine ( O.2IlCi ) by Bacillus 
licheniformis ( CDM • 37°C. 90 rpm ) ; 
• : O.OIlg/ml 
o : O.Olllg/ml 
• : O.0251lg/ml 
o : O.051lg/ml 
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3.10. Aspects of the resistance of Kl pneumoniae to pyrithione 
3. I O. I. The MIC of pyrithione against control and pyrithione-treated ceIls 
Table 3.7 shows the MIC values for pyrithione against control and pyrithione 
treated ce!!s of Kt. pneunwniae . The MIC of pyrithione against untreated cells 
( grown for 24 hours in CDM ,37°C, 90 rpm ) was 5.0J.1g1m! ( culture A ) . The 24 
hourly subculturing of these untreated cells in fresh CDM over a period of 7 days did 
not affect the MIC value, which was assessed every 24 hours immediately before 
subculturing . CeIls of Kt. pneunwniae that were incubated for 24 hours in CDM 
containing 5.0J.1g1m1 pyrithione were more resistant than untreated cells ( culture A ) 
with an MIC value of 4OJ.1g/m1 ( culture B ) , and this MIC value was not affected by 24 
hourly subculturing in pyrithione ( 5.0J.1g/m1 )-containing CDM . Cells that were 
initially incubated in CDM containing pyrithione ( 5.0J.1g1m! ) for 24 hours, then 
subcultured into drug-free CDM every 24 hours over a period of 7 days responded 
differently ( culture C ) . The MIC of pyrithione against these ceIls was 4IlI!glm! over 
the period of 4 days but was reduced to 20J.1g/m1 over the remaining period of 3 days. 
3.10.2. The effect of pyrithione on the growth curve of pyrithione-treated cells of 
Kl pnewnoniae 
The effect of pyrithione on the growth of pyrithione-treated ( grown in CDM 
containing 5.0J.1g1m! pyrithione at 37°C, 90 rpm for 24 hours) ceIls of 
Kl. pneunwniae is shown in Figure 3.39 . Pyrithione induced a lag phase the length of 
which ( approximately 60 minutes) was independent of the concentration ( 1.0 , 2.0 , 
3.0 , 4.0 and 5.0J.1g1m1 ) of the drug . The lag phase was foIlowed by growth at rate 
similar to that of the control ( pyrithione-treated cells grown in drug-free CDM ) . 
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Table 3.7 : Minimum inhibitory concentrations of pyrithione against control 
and pyrithione-treated cells of Klebsiella pneumoniae (CDM ,37°C) . 
Time (days) MIC (J!g/ml) 
Culrure A * Culrure B CulrureC 
0 5.0 40.0 40.0 
1 5.0 40.0 40.0 
2 5.0 40.0 40.0 
3 5.0 40.0 40.0 
4 5.0 40.0 40.0 
5 5.0 40.0 20.0 
6 5.0 40.0 20.0 
7 5.0 40.0 20.0 
* Culture A : cells of Klebsiella pneumoniae subculrured in drug-free CDM 
every 24 hours . 
Culrure B : cells of Klebsiella pneumoniae subculrured in CDM containing 
5.01lg/ml pyrithione every 24 hours . 
Culrure C : cells of Klebsiella pneumoniae initially grown in CDM containing 
5.01lg/ml pyrithione for 24 hours, then subculrured in drug-free 
CDM every 24 hours. 
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Figtrre 3.39 : The effect of pyrithione at various concentrations on the 
growth (CDM ,37°C, 90 rpm) of cells of Klebsiella 
pneumoniae previously grown for 24 hours in CDM ( 37°C, 
90 rpm ) containing 5.01lg/ml pyrithione ; 
• : O.Ollglml 
o : l.Ollglml 
• : 2.01lglml 
o : 3.01lglml 
~ : 4.01lglml 
+ : 5.01lglml 
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3.11. Cross-resistance of control and pyrithione-treated cells of Kt. pneumoniae and 
B. licheniformis to other antimicrobial agents 
3.11.1 Agar diffusion 
Figure 3.40 shows the zones of growth inhibition of control and pyrithione-treated 
cells of Kt. pneumoniae induced by a group of antibiotics. Control cells of 
Kl. pneumoniae were inhibited by chloramphenicol, colistin sulphate, nitrofurantoin , 
kanamycin, streptomycin and tetracycline, whilst ampicillin and suphafurazole had 
little or no effect ( Fig 40a ) . Pyrithione-treated (resistant) cells showed a similar 
pattern to that of the control ( untreated) cells with the exception that the inhibition zone 
induced by chloramphenicol has almost completely disappeared (Fig 40b ) . Inhibition 
zones of other drugs remained essentially unchanged . 
Figure 3.41 shows the zones of inhibition of control and pyrithione-treated cells of 
B. licheniformis by the same group of antibiotics. Control cells were inhibited by 
chloramphenicol, nitrofurantoin, sulphafurazole , kanamycin, ampicillin , 
streptomycin and tetracycline, but to a lesser degree by colistin suphate ( Fig 41 a ) . 
Pyrithione-treated cells were inhibited in a similar fashion and to the same extent ( Fig 
41b) . 
3.11.2. MIC determinations 
The MIC values of pyrithione , 8-hydroxyquinoline and chloramphenicol ( tube 
dilution) against Kt. pneumoniae are 5.0 , 50 and 12.51-lg/mi , respectively 
( Table 3.8 ) . Pyrithione-treated cells of Kt. pneumoniae were less sensitive than 
control ( untreated) cells to pyrithione ( MIC 401-lg/mi ) and chloramphenicol ( MIC 
lOOI-lg/ml ) but as sensitive as control ( untreated) cells to 8-hydroxyquinoline ( MIC 
50I-lg/mi ) , as shown in Table 3.8 . 
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3.12. Fatty acid content of control and pyrithione-treated cells of KZ pneumonjae 
Fatty acid contents ( GLC of methyl esters of chloroform/methanol extracts) of 
control ( untreated) and pyrithione-treated cells of Kt. pneumoniae were essentially 
similar ( Table 3.9 ) . The major fatty acids were : myristic ( C14:0 ) , palmitic 
( C16:0) , stearic ( C18:0 ) and arachidic ( C20:0 ) . Palmitic acid ( C16:O) was the 
most abundant ( 48.6-50% of total fatty acid content) whilst arachidic acid was the 
least (9.3-12.8% , Table 3.9 ) . 
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Figure 3.40 : Agar diffusion sensitivity screen ( Nutrient Agar ,37°C) of 
the following antibiotics: 
C : Chloramphenicol , 50~g , 
er : Colistin sulphate , lO~g , 
F : Nitrofurantoin , 200~g , 
SF : Sulphafurazole , 5()()~g , 
K : Kanamycin , 30~g , 
AMP : Ampicillin , 25~g , 
against : 
S : Streptomycin , 25~g , 
1E : Tetracycline , 50~g , 
(a) control cells of Klebsiella pnewnoniae . 
(b) pyrithione-treated ( grown in CDM containing 5.0~g/ml 
pyrithione at 37°C and 90 rpm for 24 hours) cells of 
Klebsiella pneumoniae . 
a 
b 
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Figure 3.41 : Agar diffusion sensitivity screen ( Nutrient Agar, 37°C) of 
the following antibiotics: 
C : Chloramphenicol, 50l1g , 
er : Colistin sulphate, 1OI1g , 
F : Nitrofurantoin , 200l1g , 
SF : Sulphafurazole , 500llg , 
K : Kanamycin, 30llg , 
AMP : Ampicillin, 25l1g , 
against: 
S : Streptomycin, 251lg , 
1E : Tetracycline, 50l1g , 
(a) control cells of Bacillus Iicheniformis 
(b) pyrithione-treated ( grown in CDM containing 0.0511g/ml 
pyrithione at 37°C and 90 rpm for 24 hours) c,ells of 
Bacillus IichenifomUs . 
a 
b 
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Table 3.8 : Minimum inhibitory concentrations ( MIC ; tube dilution; CDM ) of 
pyrithione, 8-hydroxyquinoline and chloramphenicol against control 
( untreated) and pyrithione-treated cells of Kl. pneumoniae . 
Antimicrobial 
Agent 
Pyrithione 
8-hydroxyquinoline 
chloramphenicol 
control 
5.0 
50.0 
12.5 
MIC (JJ.g!ml) 
pyrithione-treated 
40.0 
50.0 
100.0 
Table 3.9 : Fatty acids (GLC of fatty acid methyl esters) composition of control 
( untreated) and pyrithione-treated ( 5.01lg/ml ,37°C, 90 rpm , 24 hr ) 
cells of Kl. pneumoniae . 
Control ( untreated) cells 
Pyrithione-treated cells 
Myristic 
(CI4:0) 
15.4 
17.8 
113 
% of total fatty acids 
Palmitic 
(CI6:0) 
50.0 
48.6 
Stearic 
(CI8:0) 
21.8 
24.3 
Arachidic 
(C20:0) 
12.8 
9.30 
3. 13.The effect of pyrithione on the m01l'holoGY of micro-organisms 
Figures 3.42 , 3.43 and 3.44 show the scanning electron micrographs of control 
and pyrithione-treated cells of Kl. pneunwniae ,B.licheniformis and C. albicans , 
respectively. Control ( untreated) cells of K1. pneumoniae are typically shon rods 
( 3-4~ ; Fig 3.42a ) . When grown in the presence of pyrithione , some cells of 
KI. pneunwniae showed elongation. Elongated cells ( IO-20J.llIl in length) were 
observed in the presence of 2.5 and 5.0j.lg/mJ of pyrithione ( Fig 3.42 b and c ) , but 
the longest cells were observed at IOj.lg/mJ pyrithione ( Fig 3.42d) . 
Control cells of B. licheniformis are typically rod shaped ( 4-6~ ; Fig 43a ) , but 
longer than cells of KI. pneunwniae ( cf. Figs 42a and 43a ) . Pyrithione at 0.025 , 
0.05 and 0.1 j.lg/mJ ( Fig 43 b , c and d , respectively) had no apparent effect on the 
morphology of cells of B. licheniformis . 
Control cells of C. albicans are typically oval-shaped with smooth surfaces 
( Fig 44a ) . Cells grown in the presence of 0.025j.lg/ml pyrithione are similar to control 
cells and show no apparent signs of morphological alterations ( Fig 3.44b ) . Cells 
grown in the presence of 0.05 or O.lj.lg/mJ of the drug show signs of cell surface 
damage and leakage of cytoplasmic material, with these effects more evident at 
O.lj.Lg/mJ pyrithione (Fig 3.44c) than at 0.05j.lg/mJ of the drug (Fig 3.44d) . 
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Figure 3.42 : Scanning electron micrographs of cells of Kt. pneumoniae 
grown ( CDM • 37°C. 90 rpm • 24 hr ) in the presence of 
pyrithione at the following concentrations : 
(a) O.OIlg/ml ; mag. lkx . 
(b) 2.51lg/ml; mag. lkx. 
(c) 5.01lg/ml ; mag. lkx . 
(d) IO.OIlg/ml ; mag. lkx . 
, 
115a 
c 
d 
115b 
Figure 3.43 : Scanning electron micrographs of cells of B. licheniformis 
grown ( CDM • 37°C. 90 rpm • 24 hr ) in the presence of 
pyrithione at the following concentrations: 
(a) O.OI1g/mi • mag. lkx . 
(b) 0.02511g/mi ; mag. lkx. 
(c) 0.0511g/mi ; mag. 3.3kx . 
(d) O.ll1g/mi ; mag. 3.3kx . 
a 
b 
~a 
d 
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Figure 3.44 : Scanning electron micrographs of cells of C. albicans 
grown ( CDM • 37°C. 90 rpm. 24 hr) in the presence of 
pyrithione at the following concentrations: 
(a) O.Ollglml ; mag. 2.gkx . 
(b) 0.0251lglml ; mag. 2.gkx . 
(c) 0.051lglml ; mag. 2.gkx . 
(d) O.lllglml ; mag. 0.6kx. 
a 
117a 
c 
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3.14. The effect ofpyrithione on the activity of purified E coli RNA polymerase in 
yirro . 
Pyrithione , at 2.51lg/rni , caused a 70% reduction in the level of [a.32P1UTP 
incorporation into RNA transcribed by purified E. coli RNA polymerase in vitro 
compared to the control ( no drug added ; Table 3.10 ) . For comparison the effect of 
rifampicin ( 101lg/ml ) on the incorporation of radiolabelled UTP was assessed ; 
rifampicin caused a 93% reduction under the same conditions compared with the 
control ( Table 3.10 ) . 
Table 3.10 : Effects of rifampicin and pyrithione on the activity of purified E. coli 
RNA polymerase in vitro ( 37°C, 20 min. , pH 7.8) . 
Antimicrobial 
Agent 
None 
Rifampicin 
Pyrithione 
Counts per minute of 
incorporated [a-32P1UTP 
4142 
248 
1235 
118 
Percentage inhibition 
of incOlporation 
0.0 
93 
70 
CHAPTER FOUR 
DISCUSSION 
Pyrithione inhibited the growth of a wide range of micro-organisms including both 
Gram-negative and Gram-positive bacteria, and yeast (Table 3.1 ) . In general, Gram-
positive bacteria were more sensitive than Gram-negative bacteria. This is in agreement 
with earlier observations on the antimicrobial spectrum of pyrithione ( Shaw et al , 1950 ; 
Pansy et al , 1953). Ps. aeruginosa was particularly resistant (MIC 80l!glml ,table 3.1), 
and with some organisms the level of sensitivity was medium dependent (Tables 3.1 and 
3.2) . For example, the MIC of pyrithione against Ps. aeruginosa in nutrient broth 
(80l!glml , table 3.1) is four times the MIC in chemically-defined medium (20l!glml , table 
3.2). Similarly, the MIC ofpyrithione againstB.lichenifonnis in nutrient broth 
(0.6I!glml , table 3.1 ) is approximately ten times that in chemically-defined medium 
(0.05I!glml , table 3.2) . 
The fact that pyrithione is active against a wide range of micro-organisms suggests that 
it may act at a site(s) common to a variety of miCItH>rganisms ,or that pyrithione has more 
than one mode of action, thus affecting different micro-organisms in different ways. Of 
particular interest is the observed variability in the activity of pyrittrione against some 
Gram-negative but not Gram-positive bacteria or yeast. As mentioned previously (section 
3.1.) , when determining the MIC of pyrithione in nutrient broth against Kl. pneumoniae , 
Salm. abony, S. marcescens and P. vulgaris using tube dilution method, growth 
(turbidity) was always detected in some tubes containing concentrations of the drug well 
above the MIC range. This, however, was not observed when a chemically-defined 
medium was used to determine the MIC of pyrithione against Kl. pneumoniae . 
This concentration dependent reduced-enhanced activity ( paradoxical effect) of some 
antibacterial agents, also sometimes known as the ' Eagle Effect' ( Eagle and Musselman , 
1948 ; Eagle, 1951 ) has been repotted mainly with two classes of compounds: chelating 
agents and B-lactam antibiotics. Feeney et al (1957) reported that in agar diffusion assays 
of chelating agents as oxine and 5-methyl-l,10-phenanthroline against Micrococcus 
pyogenes , concentric zones (rings) of growth and inhibition were observed around fJlter 
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paper discs saturated with the chelating agent. Similar zones were observed around filter 
paper discs saturated with metal ions such as copper , iron or cobalt placed on agar medium 
containing the chelating agent. Feeney et al (1957) suggested that various metal-chelate 
complexes with different ratios of metal to ligand formed as either the cbelating agent 
diffused through the agar containing metal ions, or as the metal ion diffused through an 
agar medium containing the chelating agent. Hence a ring of no growth would be obtained 
in areas where the particular mixture was inhibitory, and a ring of growth obtained in areas 
where a different mixture was formed which was not itthibitory . 
A similar explanation has been offered for the paradoxical activity of oxine against 
S. aureus . AI: 1 oxine:Fe complex is toxic to S. aureus wheras a 2: 1 oxine:Fe complex 
is not ( Albert et ai, 1947 ; Rubbo et al , 1950 ; Albert et ai, 1953 ) . Hence 100 high or 
100 low concentrations of oxine , in relation to iron concentration , would fail to inhibit the 
growth of S. aureus which can only be achieved if the ratio ofligand to iron is 1: 1 . Albert 
et c1l (1956) reported similar results with pyrithione against S. aureus . This suggests that 
in order for pyrithione to exhibit its antibacterial activity it has to form a 1: 1 complex with 
iron . The mode of action of pyrithione would thus be identical to oxine 
(Albert, 1985 ) . 
Although such a selective and concentration dependent activity of pyrithione has been 
observed with some Gram-negative bacteria, it was not detected 'in this study' with any of 
the Gram-positive strains, including S. aureus . However, the activity of pyrithione 
against S. aureus as reported by Albert et al (1956) was observed using a simple system in 
which the medium used was glass-distilled water to which pyrithione , iron and bacterial 
cells were added, whereas, in the present sqldy , the assessment of the activity of 
pyrithione against S. aureus was carried out in a complex medium (nutrient bmth ) . 
This highlights the role of the medium in the activity of pyrithione . 
Furthermore, the fact that this type of activity is exhibited by pyrithione against some, 
but not other, micro-organisms lends support to the possibility that pyrithione acts in 
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different ways against different micro-organisms. Indeed , Husseini and Stretton (1980) 
reponed that the chelating agent phanquone (4,7-phenanthroline-5,I-quinone) showed 
concentration dependent, reduced/enhanced activity against S. aureus but not E. coli . 
This lead to the conclusion that phanquone , although acting mainly through chelation , 
acted against S. aureus through the formation of a lethal 1: 1 complex with iron . Against 
E.coli , however, its action would depend on chelating ( other) metal ions that are 
essential for the activity of metal-containing systems ( e.g. metallo-enzymes ) within the 
cell. Hence, phanquone may have a similar mode of action to that of oxine ( Husseini and 
Stretton , 1980 ) . It is , therefore, reasonable to suggest that pyrithione may have at least 
two modes of action, where against organisms like Kl. pneumoniae , Salm. abony , 
S. marcescens and P. vulgaris, the ratio of pyrithione to some metal species in the 
medium is of significance, but not against other organisms in this study. 
The concentration dependent effect discussed above is not limited to chelating agents . 
B-lactam antibiotics have recently been shown to produce such effect which may have 
clinical implications. Goldstein and Rosdahl (1981) reported the banded zone phenomenon 
around ampicillin discs tested against 76 strains of E. coli. Similar results were obtained 
with agar diffusion assays of imipenem against S. haemolyticus ( Traub , Kohl and 
Sphor, 1988). Ikeda et al (1987) , using both broth dilution and disc diffusion assays, 
reported that cefmenoxime , a broad spectrum cephalosporin, exhibited paradoxical activity 
against P. vulgaris. Compared to other cephalosporins that did not behave similarly, 
cefmenoxime at high concentrations induced higher levels of B-Iactamase to which it is 
highly sensitive (Ikeda and Nishino , 1988) . Hence, cefmenoxime shows diminished 
activity at high concentrations against P. vulgaris. In an experimental infection model in 
mice using P. vulgaris, this phenomenon was'also demonstrated ( Ikeda et ai, 1990) . 
Such findings may have implications in the chemotherapy of infections where attention has 
to be paid so that drug concentration at the site of infection does not approach a level high 
enough that could elicit such a response. The reduction of the in vitro activity of high 
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concentrations of penicillin against Enterococcus faecalis was , however, attributed to the 
reduced activity of autolytic enzymes at higher drug concentrations (Fontana et al , 1990) . 
Whatever the reasons for the paradoxical activity of some antimicrobial agents, it is 
certainly a phenomenon that occurs with a wide range of bacteria including Gram-positive 
and Gram-negative strains. 
The MIC's of four compounds, structurally related to pyrithione , against 
Kl. pneumoniae , B.licheniformls and C. albicans are shown in Table 3.3 .. The 
structures of these compounds are shown in Figure 4.1 . It is clear that non of these 
compounds showed any detectable activity against Kl . pneunwniae ( MIC > lOOI1g/ml ; 
Table 3.3. ) . Whilst neither MP nor MPY are able to chelate metal ions, both HMP and 
MNA are able to form 5- and 6-membered chelate rings, respectively. Although chelation 
is believed to be essential for the antimicrobial activity of pyrithione ( Albert et al , 1956 ) , 
our results suggest that pyrithione's activity against Kl. pneumoniae may not be solely 
due to this feature. This is indeed substantiated by the fmding that all four compounds 
inhibit the growth of B.lichenifonnis (Table 3.3. ) albeit to a lesser extent than that 
achieved by pyrithione under similar conditions ( Table 3.2. ) . Furthermore, MP , MPY 
and HMP all inhibited the growth of C. albicans similarly (MIC 12.511g/ml ; Table 3.3. ) 
but still to a lesser extent than pyrithione under similar conditions ( Table 3.2. ) . MNA , 
although able to chelate metal ions, showed no apparent inbibition of the growth of 
C. albicans ( MIC > lOOI1g/ml ; Table 3.3. ) . Hence, although chelation may play a 
significant role in the antimicrobial activity of pyrithione , other modes of action carmot be 
excluded. Further work was therefore undertaken to try to understand the nature of the 
interaction between pyrithione and Kl. pneunwniae , with B.lichenifonnis and 
C. albicans included for comparison. 
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Figure 4.1 : (a) 2-rnercaptopyridine (b) 2-rnercaptopyrirnidine 
(c) 2-rnercaptonicotinic acid (d) 3-hydroxy-2-mercaptopyridine 
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Two different growth patterns were observed in the presence of pyrithione . Bacterial 
cells of KI. pnewnoniae (Figure 3.1) andB.licheniformis (Figure 3.2) suspended in 
the chemically-defined medium containing pyrithione at various concentrations exhibited 
growth curves with distinct, extended lag phase, the extent of which was dependent on 
pyrithione concentration. This was followed by resumption of growth at a rate similar to 
that of control ( untreated) cells. Similar growth curves have been reported for cultures of 
Salmonella typhimuriwn treated with hydrogen peroxide (Watson and Schubert , 1969) . 
This was explained on the basis of the shon term instability of peroxides and the ability of 
S. typhimuriwn to breakdown H20 2 with the enzyme catalase. Although there have been 
repons of its photodegradation on exposure to ultra-violet light ( Neihof et aI , 1979 ) , 
and loss of toxicity over a 4 hour period in activated sludge ( Hyde and Nelson, 1984 ) , 
solutions of pyrithione are still active after three months at 40° C (Nelson and Hyde, 
1981) . Thus, such an instability seems unlikely for pyrithione within the experimental 
times in this study. Indeed, compound instability is further excluded as a cause of the 
growth pattern observed with bacterial cultures in the presence of pyrithione by 
observations of the different growth patterns exhibited by cells of C. albicans (Figure 3.3 ) 
growing in the presence of pyrithione in the same medium under similar conditions to tlklse 
used for bacteria. The overall effectiveness of pyrithione against C. albicans did not 
deviate markedly over the same time period ( cf. Figure 3.3 and Figs. 3.1 and 3.2 ) . Such 
yeast cells showed a drug-dependent fall in growth rate without extended lag . 
Bacterial cells are , therefore, able to survive pyrithione challenge, at low drug 
concentrations, and re-establish exponential growth at an uninhibited rate. Furthermore , 
cells of KI. pnewnoniae and B. licheniformis that have survived pyrithione treatment are 
certainly more resistant to its effects on re-challenge than cultures of similar cell density 
grown in its absence ( cf. Figs. 3.4 and 3.5 with 3.7 and 3.8 , respectively) . Again, 
C.albicans cells responded differently and rechallenging growing cultures with fresh 
pyrithione induced, in general, an additional fall in growth rate ( Figure 3.6) . Adding 
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pyrithione in mid-exponential phase to a previously untreated yeast culture inhibited growth 
( Figure 3.9 ) . Only a slight loss of sensitivity was apparent with both bacteria and yeast in 
these higher density cultures (cf. Figs 3.7. 3.8 and 3.9 with Figs 3.1. 3.2 and 3.3 ) . The 
overall pyrithione-cell ratio thus appears of slight significance and results indicate a shift in 
bacterial resistance during growth in the presence of the drug . 
Bacterial cultures are • therefore. able to 'adapt' rapidly to the presence of pyrithione 
whilst yeast cultures remain sensitive to the drug at the drug levels employed in the 
experiment. This lends further support to the suggestion that pyrithione may have more 
than one mode of action against micro-organisms as discussed above. Bacterial adaptation 
or resistance to pyrithione may be considered in the light of two alternatives: 
(1) induced changes in the majority of cells. or (2) selection of resistant cells within an 
initially heterogeneous population ( McCarthy and Hinshelwood • 1958 ) . Thus. bacterial 
cells are either adapting to the presence of pyrithione • perlJaps by creating a by-pass fo an 
essential metabolic step • or that the growth curves are reflecting the overgrowth of a 
small • inherent population of cells initially resistant to pyrithione and whose presence 
finally dominates the culture . 
Partially inhibited cultures have been studied by Rye and Wiseman ( 1968 ) who 
investigated the effects of combinations of ampicilin and other antimicrobial agents . 
Culture absorbance ( assuming no lysis) may then follow equation of the type : 
At = Ao e~t + I\, 
in which Ao is the initial absorbance of uninhibited cells. JI\, is the absorbance of non-
growing cells and A,. the absorbance of the overall culture at time (t) ; 11 is the exponential 
growth rate constant. It can be shown that cultures in which more than 99% of the 
population are unable to grow and in which the remaining cells grow at an uninhibited rate • 
would give rise to curves similar to those shown in Figures 3.1 and 3.2 . 
In order to assess whether pyrithione caused growth inhibition of the whole of the 
bacterial population of Kt. pneumoniae during the initiallag phase or whether it inhibited 
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the growth of pan of the population whilst allowing the uninhibited growth of an inherently 
resistant fraction, viability studies were undertaken using Kt. pnewnoniae and 
C. albicans for comparison of the two distinctly different growth panerns . Figure 3.10 
shows the effect ofpyrithione on the optical density (a) and viability (b) of growing 
cultures of Kt. pnewnoniae . The sets of curves for viability (Figure 3.lOb) and optical 
density (Figure 3.1 Oa) are essentially similar. Both show, in the presence of pyrithione , a 
lag phase during which optical density and viable count remain vinually constant for a time 
dependent on pyrithione concentration. This is followed by a phase during which both 
optical density and viability increase at a rate similar to that of the untreated cells . These 
results suggest that pyrithione inhibits the growth of the whole population of 
Kt. pnewnoniae for the duration of the lag phase, and that the re-establishment of growth 
is due to the adaptation of the whole population rather than the overgrowth of a fraction of 
the population initially resistant to pyrithione . 
In compllrison , Figure 3.11 shows the effect of pyrithione on the optical density (a) 
and viability (b) of growing culture of C. albicans. The reduction in the overall growth 
rate and the absence of a lag phase in cultures of C. albicans as measured by the optical 
density (Figure 3.l1a) is mirror-imaged in viable counts (Figure 3.11b) . Hence, at sub-
inhibitory levels, pyrithione does not cause complete inhibition of either growth or division 
of the yeast culture, but partial inhibition. These results support the assumption that 
pyrithione may , therefore, act through different mechanisms against bacteria and yeast. 
Further studies on the behaviour of a bacterial population of Kt. pneumoniae in the 
presence of pyrithione were conducted using a method based on that devised by Rye and 
Wiseman ( 1967 , 1968 ) .At low sub-inhibitory levels of ampicillin, bacterial cells are able 
to grow ( increase in mass) logarithmically without di \liding . Thus, under these 
conditions cells undergo an increase in size ( filamentation ) and optical density ( mass ) , 
but the viable counts remain virtually unchanged for the duration of the incubation. by 
measuring the cell size distribution of bacrerial cells such as E. coli in the presence of 
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sufficient ampicillin to suppress cellular division plus an antibacterial agent at various 
concentrations, it is possible to monitor population behaviour and relate to the presence of 
the antibacterial agent ( Rye and Wiseman , 1968) . 
Hence cells incubated in the presence of ampicillin alone would exhibit a unimodal size 
distribution with time-dependent shift in the mean size . An antibacterial compound with a 
uniform action against all cells would thus be expected to cause a time-dependent shift in 
the mean size of division-less cells. This was observed with cultures of E. coli treated 
with phenol and tetracycline (Rye and Wiseman , 1968) . Similar responses were obtained 
with isopropyl or benzyl alcohols , and with Ps. aeruginosa ( carbenicillin-treated) in the 
presence of gentamycin ( Wiseman , 1 en 4 ) . Under similar experimental conditions, 
phenylmercuric acetate caused a gradual widening of the cell size distribution and the 
continual but slow decrease in the number of cells in the lower size ranges, suggesting that 
all the cells are growing but at widely different rates ( Rye and Wiseman , 1968 ) . Thus, 
phenylmercuric acetate appears to inhibit the individual cells in a culture to different extents 
either by causing a non-uniform decrease in their rates of growth , or by imposing a lag 
period on the cells the duration of which varies from cell to cells ( Rye and Wiseman , 
1968). 
A third possible mechanism of growth inhibition was illustrated by the action of 
membrane active agents such as cetyltrimethylammonium bromide ( Rye and Wiseman , 
1968 ) , decyl- and dodecyltrimethy1amrnonium bromides, benzalkonium chloride, 
chlorhexidine and polymyxin B against E. coli (Wiseman , 1974) . In these cases, a 
bimodal distribution of cell sizes developed in the presence of the antibacterial agent 
showing the presence of two types of cells . The smaller cells which retain the size of 
untreated cells and were not growing , and the larger cells that appeared to be growing at an 
unirthibited rate ( Rye and Wiseman ,1968 ) . Hence the partial inhibition of growth caused 
by these agents resulted from completely arresting the growth of some of the cells whilst 
allowing the remainder to grow at an uninhibited rate ( Wiseman , 1974 ) . 
In the present study, preliminary studies showed that the MIC of ampicillin against 
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Kl. pneumoniae was higer than l00l1g!ml (Table 3.4 ) . However, cells grew at an 
apparently uninhibited rate in CDM in the presence of 5D11g!ml of ampicillin and under 
these conditions, a complete suppression of cell division was achieved as confIrmed by 
both (light) microscopy and viable counts. Filamentous growth was observed and the 
viable count of such cultures remained virtually unchanged over a period of three hours; no 
lysis was observed . 
Figure 3.12 shows the size distribution of growing cells of Kl. pnelUllOniae ( CDM , 
37° C , 90rprn ) at 0.0 and 120 min. times of incubation. Cells show a unimodal 
distribution with a mean size 1.2311ITI3 . An increase in mean size from 1.23 to 1.9611m3 
( Figure 3.13 ) resulted from the inhibition of cell division during incubation of the cells in 
the presence of ampicillin. The effects of pyrithione on ( ampicillin induced) division-
inhibited cells of Kt. pneumoniae are shown in Figure 3.14 .During the initiallag phase 
( 0.0 - 120 min. ) caused by pyrithione ( 211g!ml ) , the cells give rise to a unimodal 
distribution similar to that of control (untreated) cells (Figure 3.12 ) , with a mean size of 
1.2311In3 . This suggests that all the cells are unable to grow during this phase, and thus 
the action of pyrithione is exerted on the whole of the population of individual cells. 
Further incubation ( up to 480 min. ) of the cells allows growth to be re-established and 
this phase is characterised by the appearance of a bimodal size distribution (Figure 3.14 ) 
with a shift to a unimodal population with a mean size of 2.4711ITI3 . It can be concluded , 
therefore, that the effects of low concentrations of pyrithione are shon term affecting the 
whole population of bacterial cells, and resulting in an initiallag phase. Prolonged 
incubation, thus, allows the recovery of all previously inhibited cells, and that the growth 
and viability profiles of Kl. pneumoniae in the presence of pyrithione are not due to the 
overgrowth of a small unaffected population of initially resistant cells . 
The effects of oxine on microbial growth were examined for comparison with 
pyrithione . Oxine , like pyrithione , showed strong activity against B. licheniformis and 
C. albicans ( MIC's 0.625 and 0.1511g!ml , respectively; Table 3.6 ) , but was less active 
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against KI. pnewnoniae ( MIC 501lg/ml ; Table 3.6 ) . Oxine also showed two distictly 
different effects on microbial growth patterns. Against KI. pnewnoniae ( Figure 3.27 ) 
and B. lichenifonnis ( Figure 3.28 ) , oxine induced an initiallag phase, the length of 
which was proponional to drug concentration. This was followed by exponential growth 
at a rate similar to that of control ( untreated) cells. Like pyrithione , oxine induced an 
overall reduction in the growth rate of C. albicans ( Figure 3.29 ) , the extent of which 
was proponional to drug concentration. No lag phase was observed. The growth curves 
of both bacteria ( Figs. 3.27 and 3.28 ) also suggest that KI. pnewnoniae and 
B. lichenifonnis are able to rapidly overcome the action of oxine and re-establish 
exponential growth . 
Hence, pyrithione and oxine induce similar responses in the growth patterns of the 
micro-organisms tested, perhaps lending support to the assumption that these two 
compounds have similar modes of action ( Albert et al , 1956 ) . 
As has been demonstrated so far , cells of Kl. pnewnoniae are able to overcome the 
growth inhibitory effects of sub-inhibitory concentrations of pyrithione , and resume 
exponential growth . This is achieved, apparently, through the adaptation of the whole of 
the population rather than the selection of a sub-population that is inherently resistant to 
pyrithione . This is further supported by observations on the stability of this, essentially, 
pyrithione-induced resistance. Cells of KI. pnewnoniae that have been grown in the 
presence of pyrithione ( 51lg/ml ) for 24 hours show a much reduced lag phase 
( approximately 60 minutes) upon fresh challenge with pyrithione ( at 1 , 2 , 3 , 4 and 
51lg/tttl ) in CDM ( Figure 3.39 ) . The length of the lag phase is , under these conditions, 
irrespective of the concentration of pyrithione and is followed by exponential growth . The 
MIC of pyrithione against pyrithione-trained ( 24 hours; 51lg/ml ) cells of Kl. pnewnoniae 
is 401lg/ml ( Table 3.7 ) . Daily subculture of such cells in pyrithione (51lg/tttl)-containing 
CDM over a period of 7 days showed that the MIC value remained at 401lg/tttl (Table 3.7 ; 
culture B ) . However, the MIC of pyrithione against the same pyrithione-trained cells, 
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dropped from 4011g/ml to 2011g/ml after 4 daily subcultures in pyrithione-free CDM ( Table 
3.7 ; culture C ) . The MIC of pyrithione against control 
cells, subcultured daily in drug-free medium, remained at 5.011g/ml (Table 3.7 ; 
culture A) . 
The rapidity with which cells of Kl. pneumoniae adapt to the presence of pyrithione , 
and the relative ease with which such resistance is lost on growth in the absence of the 
drug , suggests that this pattern of behaviour consists of relatively unstable physiological 
adaptation of the cells to resist the action of the drug ; similar obsrvations on the adaptation 
of Aerobacter aerogenes to barbitone ( Dean and Moss, 1967 ) , and of Bact. lactis 
aerogenes to 2,4-dinitrophenol (McCarthy and Hinshelwood, 1958) have been reported 
allowing similar interpretations. 
Of particular interest, and perhaps relevance to the possible mechanism of 
Kl. pneumoniae to pyrithione , are the results on the cross-resistance of pyrithione-trained 
cells of Kl. pneumoniae to other antimicrobial agents (Figure 3.40 ) . Pyrithione-trained 
cells of Kl. pneumoniae are significantly more resistant to chloramphenicol 
( Figure 3.40a ) than control cells ( Figure 3.40b ) , as is clearly shown by comparing the 
sizes of the two respective zones of inhibition around the chloramphenicol disc 
( cf. Figs. 3.40a and b ) . This was further confirmed by MIC determinations where 
pyrithione had an MIC of 4011g/ml against pyrithione-trained cells of Kl. pneumoniae 
( compared to 511g/ml against control cells) , and chloramphenicol had an MlC of 
l00l1g/ml against pyrithione-trained cells ( compared to 12.511g/ml against control cells; 
Table 3.8 ) . Pyrithione-trained cells of Kl. pneumoniae , interestingly, showed no 
apparent cross-resistance to any of the other antimicrobial agents tested ( cf. Figs. 3.4Oa 
and b). 
To examine the relationship between the resistance of pyrithione-trained cells of 
Kl. pneumoniae to pyrithione and chloramphenicol, consideration of the commonly 
known mechanisms of bacterial resistance to chloramphenicol is essential. Bacterial 
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resistance to chloramphenicol may be achieved by plasmid-encoded enzyme, 
chloramphenicol acetyl ttansferase (CAn that catalyses acetylation of chloramphenicol with 
acetyl coenzyme A , the product of which is non-inhibitory to ribosomal protein synthesis 
( Sands and Shaw , 1973; Martinez-Suarez et ai, 1985 ; Roberts et al , 1985 ; 
Powell et ai, 1989) . Although CAT-mediated chloramphenicol resistance is the most 
frequently reponed mechanism in Gram-negative bacteria (Burns et al , 1985 ) , three 
other mechanisms have been reported . The first involves a permeability barrier , possibly 
through the lack of one or more of the outer-membrane proteins ( Burns et al , 1985 , 
1986 , 1989 ) . The second mechanism involves the reduction of the ni(o ( - N02 ) group, 
essential for antimicrobial action in chloramphenicol ( Smith and Worrel , 1953 ; Merkel 
and Steers, 1953 ; Herman and Steers, 1953 ; O'Brien and Morris, 1971 ) . Thirdly, 
mutants of Bacillus subtilis have been isolated that have decreased ribosomal sensitivity to 
chloramphenicol (Osawa et al , 1973) . 
In trying to understand how pyrithione-resistant cells of Kl. pneumoniae become 
more resistant to chloramphenicol, it is reasonable to suggest that the mechanism of 
resistance ( adaptation ) in this case is : (1) inducible over a short period of time , 
(2) unstable and may be lost on successive incubations in pyrithione-free medium and 
(3) involves a physiological adaptation rather than a specific genetic alteration. These are 
the characteristics so far concluded for the adaptation of Kl. pneumoniae to pyrithione and 
consequently may apply to the observed adaptation to chloramphenicol. 
Chloramphenicol resistance mediated by CAT, reduced ribosomal sensitivity or 
reduced permeability, result from genetic alterations ( aquisition of genetic material such as 
the gene coding for CAT, or mutations in the other two cases) , that occur at low 
frequency and are stable. On the other hand, the ability of E. coli to reduce the nitro 
group in chloramphenicol, and thus become resistant to the drug , is achieved through 
training of the cells by exposure to gradually increasing concentrations of chloramphenicol 
( Merkel and Steers, 1953) . In addition, such cells lose their resistance rapidly when 
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subcultured into chloramphenicol-free medium (Hemnann and Steers, 1953 ) . 
Funhennore , cells adapted to chloramphenicol in this manner , are able to reduce a wide 
range of nitro-aryl compounds, some of which· are derivatives of chloramphenicol ( Smith 
and Wonel, 1953) ,whilst others are not (O'Brien and Morris, 1971 ). Egarni et al 
( 1951 ) reported that inorganic nitrite interferes with the enzyrnatic reduction of 
chloramphenicol ( and vice versa) by bacterial cell-free extracts of Streptococcus 
haemolyticus . They indicated that chloramphenicol and nitrite were probably reduced by 
the same enzyme system, although Saz and Slie ( 1954) , working with E. coli extracts , 
concluded that the two enzyme systems were different. 
Since the N- oxide group is essential for the antimicrobial activity of pyrithione , it is 
possible that the adaptation of Kl. pnewnoniae is mediated by an inducible enzyme 
system(s) able to reduce the N- oxide group and thus account for the rapid recovery of the 
cells. The same system(s) may be able to reduce the nitro group of chloramphenicol, 
hence resulting in the observed cross-resistance. In this context, the length of the lag 
phase observed with cultures of Kl. pnewnoniae in the presence of pyrithione 
( Figure 3.1) would reflect the time required to reduce the concentration of active pyrithione 
below inhibitory levels, which would then allow the re-establishment of exponential 
growth . 
Although cells of B .licheniformis exhibit a similar growth pattern in the presence of 
pyrithione (Figure 3.2 ) to that of Kl. pnewnoniae ( Figure 3.1 ) , pyrithione-trained cells 
of B. licheniformis do not show any apparent cross-resistance to any of the antimicrobial 
agents tested, including chloramphenicol ( cf. Figs. 3.4la and b) . The mechanism of 
resistance ( adaptation) of B. licheniformis to pyrithione does not, therefore, result in 
cross-resistance to any of the animicrobial agents tested . 
Pyrithione-trained cells of Kl. pnewnoniae are as sensitive to oxine as control cells 
( Table 3.8 ) . Oxine has an MIC of 4Ojlg/ml against both types of cells. Although it has 
been suggested that oxine has a similar mode of action to pyrithione ( Albert et al , 1956 ) , 
pyrithione differs structurally from oxine . If the mechanism of resistance ( adaptation) to 
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-pyrithione involves the reduction of the N- oxide group in the molecule, as has been 
suggested above, then it is unlikely to result in resistance to oxine , since the latter does not 
have a similar functional group that might be reduced via the same enzyme system(s) . 
Indeed, the inability of pyrithione-trained cells of KI. pneumoniae to exhibit increased 
resistance to oxine lends further support to the possibility that such resistance to pyrithione 
results from the modification of the drug rather than a possible alteration of the site(s) of 
action. 
Analysis and comparison of fany acid profiles of both control and pyrithione-treated 
cells of KI. pneumoniae showed, essentially, no differences (Table 3.9 ) . The main 
fany acids in both cells were myristic, palmitic , stearic and arachidic acids . Variations in 
fany acids proffies have been associated with the adaptation of bacteria to antimicrobial 
agents such as in the case of adaptation of Ps. aeuginosa to polymyxin B (Conrad and 
Galanos , 1989 ) , were such alterations result in reduced permeability of the cell envelope 
and hence exclusion of the drug . In the case of pyrithione initial analysis showed no 
significant alterations in fany acid proffies between pyrithione-sensitive and pyrithione-
treated cells of KI. pneumoniae . That the adaptation of KI. pneumoniae to pyrithione 
could be due to structural alterations in the cell envelope leading to reduced uptake of the 
drug is , therefore, unlikely .The adaptation of KI. pneumoniae to pyrithione is most 
likely the result of an inducible biochemical event rather than any major structural change. 
The effects of pyrithione on both bacteria and yeast were antagonised by the chelating 
agent EDTA (Figure 3.15). The antagonism was most detectable with B. Iicheniformis 
(Figure 3.15b) and C. albicans (Figure 3.15c), and less so with KI.pnewnoniae 
(Figure 3.15a) . Further confirmation of this antagonism was demonstrated in growth 
studies in which EDT A shortened the pyrithione-induced Jag phase in bacterial cultures of 
KI.pneumoniae (Figure 3.16) andB.licheniformis (Figure 3.17) ,and increased the 
growth rate ofpyrithione-treated cells of C. albicans (Figure 3.18 ) . EDTA itself had no 
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-apparent inhibitory action against either Kt. pneumoniae or B. lichenifonnis (MIC> 
200llglml; Table 3.5 ) , but cells of C. albicans were inhibited by EDTA (MIC 501J.gIml ; 
Table 3.5). 
Although EDTA exhibits strong antibac terial ( lytic) activity against Pseudomonas 
species ( Eagon and Carson , 1964 ) , its main antimicrobial value and use has been the 
potentiation of the action of other antimicrobial agents ( Hart , 1984 ) , through chelation of 
Mg2+ and ea2+ ions normally responsible for outer-membrane stability in Gram-negative 
organisms (Denyer, 1985). However, Neu and Winshell ( 1970) reponed that EDTA 
did not enhance the activity of ampicillin, chloramphenicol or tetracycline in strains of 
EnJerobacteriacae . In the case of pyrithione , EDT A positively antagonised the actions of 
pyrithione against both bacteria and yeast (Figures 3.15,3.16,3.17 and 3.18). This 
suggests a significant role for divalent cations present in the medium in the action of 
pyrithione ( Albert , 1956) and for which pyrithione and EDT A could compete. This is to 
some extent supponed by observations of the growth of some Gram-negative bacteria such 
as Kt. pneumoniae , Salm.abony , S. marcescens and P. vulgaris in the presence of 
'high' pyrithione concentrations that should have been inhibitory ( section 3.1. ) , perhaps 
due to variation in the pyrithione/cation ratio as discussed above. The strong antagonism 
between EDT A and pyrithione would, therefore, limit the possibility of using both these 
agents , in combination , for preservation of industrial products or for therapy such as in 
anti -dandruff formulations . 
The possible effects of some metal ions on the antimicrobial activity of pyrithione were 
tested in a similar manner as with EDT A using the agar-diffusion method ( Maccacaro , 
1961 ) . A general observation on the results of these experiments is that none of the five 
metal ions tested ( Fe3+ , Mg2+ , Mn2+ , Zn2+ and ea2+ ) antagonised the action of 
pyrithione against any of the three micro-organisms tested ( KI. pneumoniae , 
B.lichenifonnis and C. albicans) in either nutrient agar or CDMA (Figs. 3.19 to 3.24). 
Using the strip method (Mccacaro, 1961 ), Husseini and Stretton ( 1980) showed 
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antagonism between each of c02+ , Cu2+ , Fe3+ , Fe2+ , Zn2+ and phanquone against 
E. coli as well as antagonism between each of C02+ , Cu2+ , Fe3+ , Fe2+ , Ni2+ and 
phanquone against S. aureus . Metal ions, therefore, probably rendered phanquone 
inactive either by filling its complexing sites, hence becoming unable to complex with 
metals in bacterial metal-containing systems ( e.g. meta11o-enzymes ), and I or by 
rendering phanquone impermeable through the bacterial cell wall or membrane, thus 
becoming unable to reach its site of action ( Husseini , 1978 ; Husseini and Stretton , 
1980). 
The lack of antagonism between pyrithione and the metal ions in this study, however , 
does not necessarily lead to the conclusion that metal ions play no essential role in the 
activity of pyrithione , since EDTA antagonises the action of pyrithione and the paradoxical 
activity of pyrithione against some gram-negative bacteria is consistent with observations 
with other antimicrobial chelators ( Albert et aI , 1953 ; Feeney et al , 1957; Husseini and 
Stretton , 1980 ) . It must be emphasized that the strip method is a crude method to measure 
possible interactions between various substances against micro-organisms . And whilst 
clear results are obtained between pyrithione and EDT A , the interaction between pyrithione 
and metal ions is , undoubtedly, influenced by the presence of a variety of metal ions in the 
medium itself . 
The influence of the medium composition on the interaction of pyrithione with various 
metal ions is clearly illustrated by comparing the results obtained using nutrient agar with 
those using CDMA . Whilst only Zn2+ ( Figure 3.19a ) enhanced the activity of pyrithione 
against Kl. pneumoniae in nutrient agar, both Zn2+ ( Figure 3.22a ) and Fe3+ (Figure 
3.22e) enhanced the activity of pyrithione against the same organism in CDMA . Both 
Mg2+ ( Figure 3.20b ) and ea2+ (Figure 3.2Od ) slightly enhanced the activity of 
pyrithione against B .lichenifonnis in nutrient agar but not in CDMA ( Mg2+:Figure 3.23b ; 
ea2+:Figure 3.23d ) . Fe3+ slightly enhanced the action of pyrithione against 
B. licheniformis in both nutrient agar ( Figure 3.2Oe ) and CDMA ( Figure 3.23e ) , whilst 
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Zn2+ and Mn2+ showed some potentiation of pyrithione's action in COMA ( Figs. 3.23a 
and c , respectively) but not in nutrient agar ( Figs. 3.20 a and c , respectively) . 
Furthermore, only Zn2+ ( Figure 3.24a ) enhanced the action of pyrithione against 
C. albicans in COMA , wherEUJSpyrithione's activity was enhanced by all of the metal ions 
tested: Zn2+ , Mg2+ , Mn2+ , Ca2+ and Fe3+ ( Figs. 3.21a ,b , c , d and e , respectively) 
against C. albicans in nutrient agar . 
The results highlight the non-specific nature of chelation ( Dwyer and Mellor , 1964 ) , 
in that a given chelating agent will combine with metal ions in general. In a metal-rich 
environment, such as growth media, a variety of chelates may be formed, and some of 
these chelates in the case of pyrithione , do enhance its antimicrobial activity as seen in 
Figures 3.19 to 3.24 . The role of Fe3+ in the antimicrobial activity of pyrithione ( Albert 
et al , 1956 ) is not, therefore, necessarily specific or peculiar to this metal ion, since the 
co-operative effect between Fe3+ and pyrithione was demonstrated in a medium 
( theoretically) devoid of any other metal ions ( glass-distilled water) . It is reasonable to 
suggest that through chelation of metal ions in the medium, pyrithione permeates the cell as 
a chelate and exerts its toxic action within the cell. The potentiation of pyrithione by some 
metal ions may , therefore, reflect the improved permeability of the microbial cell to such 
complexes compared to others . 
The morphology of C. albicans was more obviously affected by pyrithione . Control 
cells of C. albicans were oval-shaped with smooth appearance ( Figure 3.44a ) . 
Incubation in the presence of pyrithione ( COM ,37°C, 24hr ) , caused some structural 
damage characterised by the collapse of cells accompanied with obvious damage to the cell 
exterior and leakage of cytoplasmic material . These effects were more apparent at higher 
concentrations of the drug ( 0.025 , 0.05 and O.IjJ.g/rnl ; Figs. 3.44 b , c and d , 
respectively) . Pyrithione may, therefore, cause structural damage to the yeast cell 
envelope, particularly since Chandler and Segel ( 1978) suggested that pyrithione's site of 
action in fungi is the cytoplasmic membrane . Short term incubation of bacteria with levels 
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of pyrithione equal to or greater than the MIC did give rise to fIlaments with 
KZ. pneumoniae ( cf. Figs 3.42a with 3.42b , c and d ) , though this was not observed 
with B. licheniformis ( Figs 3.43 a , b , c and d ) . Since no seen evidence of structural 
damage was detected, it is likely that pyrithione exherts its antibacterial effect by more 
subtle influences on cellular biochemistry . 
Some evidence was obtained, during this study, as to the likely site of antibacterial 
activity ofpyrithione .The effects ofpyrithione on the synthesis of DNA ,RNA and 
proteins were asessed by following the incorporation of 14C-thymidine , 14C-uridine and 
14C-glycine , respectively, in cells of KZ. pneumoniae in the absence and presence of the 
drug . Short term studies ( up to 30 minutes) showed that pyrithione blocked further 
incorporation of glycine ( Figure 3.30) , thymidine ( Figure 3.32 ) and uridine ( Figure 
3.34) in KZ. pneumoniae within 2-3 minutes of the addition of the drug at concentrations 
( I ,2.5 and 5J.Lg/ml ) that are growth-inhibitory ( Figure 3.1 ) . It appeared, therefore , 
that concentrations of pyrithione that induce a lag phase also inhibit the uptake and / or 
incorporation of glycine, thymidine and uridine in proteins, DNA and RNA, 
respectively. However, since pyrithione-treated cells of KZ. pneurrwniae are able to re-
establish growth at rates similar to that of untreated cells ( Figure 3.1 ) , it was essential to 
monitor the incorporation of radiolabelled substrates by KZ. pneurrwniae once the cells 
have re-established growth in the presence of pyrithione . 
Prolonged incubation ( 300 - 400 min. ) of KZ. pneumoniae in the presence of 
2.5J.Lg/ml of pyrithione allows the re-establishment of exponential growth ( Figure 3.1 ) . 
Under these conditions, the incorporation of 14C-thymidine remained inhibited ( Figure 
3.33 ) , and the incorporation of 14C_glycine resumed but at a reduced rate compared with 
control ( untreated) cells ( Figure 3.31 ) . Interestingly, the incorporation of 14C-uridine 
resumed ( as the cells started to grow after the initiallag phase) at a rate similar to that of 
control (untreated) cells ( Figure 3.35 ) . 
Similar irreversible inhibition of thymidine uptake by pyrithione has been reported for 
human leukaemic cells ( Kontoghioghes et al , 1986; Forsbeck et aZ , 1987 ) , and 
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interpreted as indicating a direct effect on DNA synthesis. However, in the case of Kl. 
pneumoniae , culture survival does not seem affected by this inhibition since the onset of 
the exponential phase of growth occurs at a time when inhibition of thymidine 
incorporation is still demonstrable ( cf. Figs 3.1 and 3.33 ) . The explanation for this may 
be found by examining the pathway of the incorporation of external thymidine in the DNA 
of the cell . Before being incorporated into bacterial DNA, external thymidine has to 
undergo phosphorylation to yield thymidine triphosphate ( TIP ) by the so called 'salvage' 
pathway ( Adams et al , 1981 ) : 
Thymidine» d1MP » dlDP » d1TP , 
where d1MP , dlDP and dTIP are deoxythymidine monophosphate, - diphosphate and 
- triphosphate, respectively. The salvage pathway exists in bacteria ( Nelson and Carter, 
1969 ; Black and Hruby , 1991 ) ,yeast (long and Campbell , 1984 ) and mammalian cells 
( Grav and Smellie , 1963; 1965 ) . The frrst step in this pathway, the production of d1MP 
from thymidine and A TP , is catalysed by the enzyme thymidine kinase 
( Black and Hruby , 1991 ) . The sequencial production of dlDP and d1TP is catalysed by 
thymidylate kinase (Nelson and Carter, 1969) . Both enzymes require Mg2+ as a cofactor 
, although it could be replaced partially by either Mn2+ or Co2+ in the case of thymidylate 
kinase ( Nelson and Carter, 1969 ) . It is possible that pyrithione , through chelation of 
Mg2+ , could inhibit either or both enzymes and thus completely block the incorporation of 
14C-thymidine in Kl. pneumoniae . 
Such inhibition, however, was not det. rimental to the survival of cells of 
Kl. pneumoniae since bacteria are able to produce dTIP , essential for DNA biosynthesis 
through the following steps: (1) reduction of uridine diphosphate ( UDP ) to deoxyuridine 
diphosphate ( dUDP ) by the enzyme ribonucleotide reductase, (2) phosphorylation of 
dUDP to deoxyuridine triphosphate (dUTP) followed by rapid hydrolysis by the enzyme 
dUTPase to yield dUMP , (3) methylation of dUMP to d1MP by thymidylate synthetase , 
and fmally (4) phosphory lation of d1MP to produce dTIP , which is then incorporated into 
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DNA (Adams et ai, 1981 ) . Whilst the enzyme thymidylate kinase catalyses the essential 
metabolic step dTMP» dTfP, the phosphorylation of thymidine to give dTMP is 
probably not an essential step for the survival of bacterial cells. TIris is supported by the 
isolation a mutant of E. coli ( strain KY608 ) ,deficient in thymidine kinase activity, that 
is able to grow normally in general medium (Higara et al , 1967 ; Igarashi et al , 1967 ; 
Black and Hruby , 1991 ) . 
The irreversible inhibition by pyrithione of the incorporation of extracellular 
14C-thymidine in Kl. pneumoniae ( Figure 3.33 ) during the initiallag phase and the 
. subsequent phase characterised by normal growth and division ( cf. Figs. 3.33 and 3.1 ) , 
could be the result of an irreversible inhibition of the enzyme thymidine kinase , perhaps 
through chelation of the cofactor Mg2+ . Any possible inhibition of thymidylate kinase 
would have to be reversible in order for the cells to recover from the growth inhibitory 
effects of pyrithione . 
Just as the inhibition of thymidine incorporation into cells of Kl. pneumoniae could not 
account for the growth inhibition by pyrithione , so could not the partial inhibition of 
14C-glycine incorporation by pyrithione ( Figs. 3.30 and 3.31 ) . Shon tenD experiments 
( up to 30 min. ) showed complete inhibition of glycine incorporation by pyrithione 
( Figure 3.30 ) . However, glycine incorporation continued at a reduced rate ( compared to 
untreated cells) throughout the initiallag phase and the subsequent exponential phase of 
growth once the cells have recovered from the effects ofpyrithione (cf. Figs. 3.1 and 
3.31) . The inhibition of glycine uptake could be due to an inhibition of a membrane 
transport mechanism similar to that shown in yeast in the presence of pyrithione ( Chandler 
and Segel , 1978 ) . Such an inhibition is both panial and long term (persisting after the 
recovery and resumption of growth ) in Kl. pneumoniae , but could not account for the 
growth inhibitory action of pyrithione , since, as mentioned above, cells are able to grow 
and divide at a rate similar to that of untreated cells, whilst the inhibition of glycine 
incorporation is still demonstrable (cf. 3.1 and 3.31 ) . 
139 
The inhibition of 14C-uridine incorporation in the RNA of Kt. pnewnoniae by 
pyrithione is , probably, the most interesting and relevant to the possible mechanism(s) of 
growth inhibition. Short term ( up to 30 min. ) experiments showed that pyrithione ( at 1, 
2.5 and 511g1ml ) completely inhibited the incorporation of uridine in Kt. pneumoniae 
( Figure 3.34 ) . however, prolonged incubation ( 300 min. ) of the cells with pyrithione 
( 2.511g1ml ) ( allowing recommencement of exponential growth ) showed the resumption 
of uridine incorporation at a rate similar to that of untreated cells ( Figure 3.35 ) . 
RNA synthesis is mediated by the RNA polymerase, the activity of which depends on 
the dissociable cations Mn2+ and Mg2+ , and on Zn2+ which is tightly bound to the enzyme 
( Scrutton et al , 1971 ; Valenzuela et at , 1973 ) . It is conceivable that pyrithione , 
through chelation of anyone or more of these ions, inhibits RNA polymerase leading to 
cessation of uridine incorporation and growth . Indeed, pyrithione ( 2.511g1ml ) caused a 
70% inhibition of DNA-directed synthesis of RNA by purified E. coli RNA polymerase 
in vitro, compared with a 93% inhibition of the enzyme by rifampicin ( IOI1g/ml ; Table 
3.10 ) . 
Further support for this comes from studies of two antimicrobial agents, namely, 
8-hydroxyquinoline ( oxine ) and diallyl thiosulfinate ( allicin) . Fraser and Creanor 
( 1974) showed that oxine caused rapid and selective inhibition of RNA synthesis in 
Schizosaccharomyces pombe as measured by the incorporation of radio labelled uridine . 
Further in vitro experiments using isolated RNA polymerase from E. coli showed that 
this inhibition can be reversed by the addition of extra Mg2+ and Mn2+ to reactions inhibited 
by oxine (Ronald et al, 1975) . Oxine also inhibits RNA synthesis in plant cells 
presumably through chelation of Mg2+ and Mn2+ associated with RNA polymerase 
( Ferrero and De La Tore, 1986 ) . Since pyrithione is thought to have a sinrilar mode of 
action to that of oxine ( Albert , 1985 ) , a selective but reversible inhibition of RNA 
polymerase, possibly through chelation of Mn2+ or/and Mg2+ , may explain the pattern of 
inhibition and resumption of uridine uptake in Kt. pneunwniae . 
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The antimicrobial action of allicin ( ~C=CH~-SO-S-CH~=CH2 ) 
against Salmonella typhimurium , may also be comparable to that of pyrithione against 
KI. pneumoniae . Feldberg et al ( 1988 ) showed that, in cells of Salm. typhimurium , 
allicin induced a lag phase whose duration was proportional to allicin concentration. This 
was followed by resumption of growth at a slightly lower rate than control ( untreated ) 
cells . Their studies on the incorporation of radiolabelled leucine, thymidine and uridine 
showed that the incorporation of uridine was inhibited in a way which mirrored the growth 
inhibition pattern of allicin against Sa/m. typhimurium . The incorporation of radiolabelled 
leucine and thymidine were only partially inhibited by allicin and were restored to normal 
level even before the full restoration of uridine incorporation to control levels . 
Feldberg et al ( 1988) concluded that allicin may selectively inhibit RNA synthesis by 
inhibiting RNA polymerase. The ability of cells of Sa/m. typhimurium to recover from the 
effects of allicin was attributed to their ability to metabolise allicin to a non-inhibitory 
compound or/and to titration of allicin with 'noncritical' targets, thus decreasing its 
interaction with critical targets, especially since the duration of the lag phase was inversely 
proportional to culture density ( Feldberg et al , 1988 ) . 
Pyrithione may inhibit the growth of KI. pneumoniae by inhibiting RNA polymerase 
through the chelation of its metal cofactors . The recovery of KI. pneumoniae may be due 
to the cell's ability to metabolise the drug . The irreversible inhibition of extracellular 
thymidine incorporation and the partial inhibition of glycine incorporation by pyrithione 
represent other effects and possibly partial damage to certain targets in the cell, but do not 
reflect accurately, in this case, the ability of cells to recover from the growth inhibitory 
action of the drug . Although allicin and pyrithione are not structurally related, both have 
an oxide group ( N- 0 , pyrithione; S- 0 , allicin) which is essential for the 
antibacterial properties of the compound ( Small et al , 1947 ; Leonard et al , 1956) . 
The short term effects of pyrithione on the incorporation of radiolabelled substrates by 
cells of B. Iicheniformis were also examined for comparison. Again, as with 
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KZ. pneumoniae • pyrithione inhibited further incorporation of 14C-glycine 
( Figure 3.36 ). 14C-thymidine ( Figure 3.37 ) and 14C-uridine ( Figure 3.38) by cells of 
B. lichenifonnis within 2-5 minutes of the addition of the drug . Based on these shon term 
effects. pyrithione appears to have similar effects on both B. lichenifonnis and 
KZ. pneumoniae in line with the similar growth patterns exibited by these two organisms 
( Figs. 3.2 and 3.1 • respectively) in the presence of pyrithione . It remains to be seen 
whether the recovery of B. lichenifonnis from the initial pyrithione-induced lag phase is 
reflected by a resumption of incorporation of any of the three radiolabelled substrates • in 
panicular • uridine . 
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Conclusions 
Pyrithione exhibits a mainly biostatic activity against a wide range of micro-organisms , 
with Gram-positive bacteria and yeast being more sensitive to the drug than Gram-negative 
bacteria. Pyrithione , however, may have more than one mode of action against different 
organisms. 
Pyrithione exhibits the phenomenon of 'concentration quenching' against some Gram-
negative bacteria but not against Gram-positive bacteria or yeast. At high concentrations, 
pyrithione is ineffective against KI. pneumoniae , Salm. aborry , S. marcescens and 
P. vulgaris; a phenomenon observed with other chelating agents such as 
8-hydroxyquinoline and believed to reflect the importance of drug : metal ion(s) ratio 
( in the medium) in the activity of the drug . Metal ions play an important role in the 
antimicrobial activity of pyrithione , as the activity of the drug is reversed by 
ethylenediaminetetraacetic acid (EDTA ) . 
The responses of bacteria and yeast to pyrithione are distinctly different. Sub-
inhibitory concentrations of pyrithione induce a lag phase in bacterial growth 
(KI. pneumoniae and B. Iicheniformis ) , the length of which depends on the drug 
concentration. Pyrithione-induced lag phase in KI. pneumoniae results from inhibition 
of all cell growth and division, and the resumption of growth which follows signals the 
ability of the whole population to overcome the effects of the drug . In contrast, yeast cells 
of C. albicans exhibit a drug-concentration-dependent reduction in growth rate, in the 
presence of pyrithione, with no apparent lag phase . 
Once exponential growth is re-established in bacterial cultures treated with pyrithione , 
such cultures become resistant to further challenge by pyrithione at levels equivalent to 
those initially present . Yeast cells do not develop such tolerance. 
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Pyrithione has been shown to interfere in the processes of uptake and/or incorporation 
of substrates into DNA, RNA and proteins in both KI. pneumoniae and 
B.licheniformis . However, only the uptake{mcorporation profiles ofuridine into RNA 
of Kl. pneumoniae reflected accurately the growth inhibition pattern of an initiallag phase 
followed by exponential growth .In vitro assay of purified E. coli RNA polymerase 
activity showed that pyrithione inhibited this enzyme by 70% compared to the control. 
It is concluded that the main site of pyrithione's action against bacteria is protein synthesis, 
at the level of RNA synthesis by inhibition of RNA polymerase, possibly through 
chelation of metal ions ( such as Mn2+ , Mg2+ or Zn2+ ) essential for the activity of this 
enzyme. 
Furthermore, cells of KI. pneumoniae that are pyrithione-trained exhibit increased and 
significant tolerance towards chloramphenicol, but not 8-hydroxyquinoline . The 
resistance of Kl. pneumoniae to pyrithione can be lost after successive sub-culturing in 
drug-free medium. In addition, pyrithione-treated cells of KI. pneumoniae do not differ 
in their fatty acids profiles from control ( untreated) cultures. The ability of 
KI. pneumoniae to overcome the action of pyrithione may be due to the cells' ability to 
metabolise the drug into a non-toxic species, possibly by reduction of the N-oxide group 
essential for the activity of pyrithione. 
Pyrithione's effects on the morphology of Kt. pneumoniae are limited to filamentation 
of some cells at high concentrations of the drug . Pyrithione causes no apparent change in 
the morphology of B. lichenifonnis , but some damage to cells of C. albicans is observed 
at higher concentrations of pyrithione . 
The observations on the interaction of pyrithione with KI. pneumoniae are consistent 
with it acting at a biochemical rather than structural level . Protein synthesis, and in 
particular RNA synthesis, appears to be the major target. 
144 
Proposals for further work 
Further work on the antimicrobial action of pyrithione could focus on aspects of the 
aquired tolerance of Gram-positive bacteria, such as B. licheniformis ,to pyrithione . In 
particular the profiles of uptake! incorporation of radioIabelled substrates (e.g. uridine ) 
... 
into sensitive as well"tolerant cells. This would be comparable to the work on 
Kt. pneumoniae in this study and would show whether the response of Gram-positive 
bacteria is similar to that of Gram-negative bacteria. In addition, analysis of protein 
profiles ( e.g. gel electrophoresis) of bacterial cells such as Kt. pneumoniae , before , 
during and after pyrithione-induced lag phase may show significant differences that would 
aid in understanding the mechanisms of inhibition and recovery observed in this study. 
The use of radiolabelled pyrithione would be very beneficial in following the uptake of 
the drug into bacterial cells, as well as its possible breakdown. The rate of uptake, and 
the site at which pyrithione may be localised within the cell may be determined and would 
enhance our understanding of how pyithione and similar substances exen their action 
against micro-organisms . 
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